Enzymatic transamination of cyclopamine analogs

Description

BACKGROUND

Cyclopamine, a natural product isolated from Veratrum californicum, has emerged as a significant pharmacological tool to validate the Hedgehog (Hh) pathway in cancer. Cyclopamine directly acts on SMO and inhibits tumor growth in several murine models of pancreatic, medulloblastoma, prostate, small cell lung, and digestive tract cancers. However, the clinical development of cyclopamine as a therapeutic in cancer is hampered by its poor solubility, acid sensitivity, and weak potency relative to other reported small-molecule Hh antagonists.

There has been considerable focus on the development of novel cyclopamine analogues with improved potency, and improved pharmacokinetic and pharmaceutical properties relative to cyclopamine (s ee, for example, U.S. Pat. Nos. 7,230,004 and 7,407,967, incorporated herein by reference). From that effort, a seven-membered D-ring sulfonamide analogue of cyclopamine, IPI-926, emerged as a clinical development candidate (see Tremblay et al., “Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)” J. Med. Chem. (2009) 52:4400-4418, incorporated herein by reference). Large quantities of IPI-926 are required for clinical development. Moreover, other promising amino analogues can be synthesized following routes similar to that used to generate IPI-926.

embedded image

SUMMARY

Provided are novel processes for the synthesis of amino analogues, such as IPI-926, from ketone starting materials,

For example, in one aspect, provided is a process for preparing a compound of formula (II):

embedded image

or a salt thereof;

from a compound of formula (I):

embedded image

or a salt thereof;

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, and X are as defined herein,

the process comprising contacting a compound of formula (I) or a salt thereof, an amino donor molecule, and an amine transaminase enzyme in a solution to provide a compound of formula (II) or a salt thereof.

In certain embodiments, the process further comprises adding a co-factor to the solution.

In certain embodiments, the co-factor is pyridoxal phosphate (PLP).

In certain embodiments, the co-factor is a co-enzyme. In certain embodiments, the co-enzyme is selected from L-alanine dehydrogenase (LADH), lactate dehydrogenase (LDH), nicotinamide adenine dinucleotide phosphate (NADPH), nicotinamide adenine dinucleotide (NAD), formate dehydrogenase (FDH), and glucose dehydrogenase (GDH).

In certain embodiments, process further comprises adding a pyruvate reductase mix to the solution. As used herein, the term “pyruvate reductase mix” refers to a combination that includes an enzyme that is capable of mediating the reduction of pyruvate and one or more (e.g., 1, 2, 3, 4, 5, or 6, e.g., 2, 3 or 4, e.g., 2 or 3) additional agents (e.g., an enzyme, a co-enzyme or co-factor, a reducing agent as well as combinations thereof).

In embodiments, the enzyme that is capable of mediating the reduction of pyruvate is LDH.

In embodiments, the combination includes an agent (e.g., an enzyme) that is capable of regenerating a co-enzyme or co-factor that mediates pyruvate reduction. In certain embodiments, the combination can include an enzyme that is capable of regenerating NADPH. Such enzymes can include, without limitation, GDH and FDH.

In embodiments, the combination includes a reducing agent. Reducing agents can include, without limitation, glucose or formate.

In embodiments, the combination includes a co-enzyme or co-factor. Co-enzymes or co-factors can include, without limitation, NAD.

In embodiments, the combination includes an agent (e.g., an enzyme) that is capable of regenerating a co-enzyme or co-factor that mediates pyruvate reduction as defined anywhere herein; and one or more additional agents (e.g., 2 or 3 additional agents). For example, the combination can include an agent (e.g., an enzyme) that is capable of regenerating a co-enzyme or co-factor that mediates pyruvate reduction as defined anywhere herein; and one or both of the following: a reducing agent and a co-enzyme or co-factor.

In embodiments, a pyruvate reductase mix includes LDH, an agent (e.g., an enzyme) that is capable of regenerating a co-enzyme or co-factor that mediates pyruvate reduction as defined anywhere herein; and one or more additional agents (e.g., 2 or 3 additional agents); e.g., one or both of the following: a reducing agent and a co-enzyme or co-factor. For example, a pyruvate reductase mix can include LDH, GDH, and glucose and can further include NAD, e.g., PRM-102 (Codexis), which includes LDH, GDH, glucose, and NAD⁺. As another example, a pyruvate reductase mix can include LDH, FDH, and formate and can further include NAD.

In certain embodiments, when pyruvate is generated during the course of the processes described herein, the pyruvate can be removed, chemically converted to another product and optionally further removed; or recycled (or combinations thereof). Methods describing such operations are described in, e.g., Koszelewski, D., et al., Trends in Biotechnology 2010, 28, 324-332, which is incorporated herein by reference in its entirety.

In certain embodiments, the enzyme preferentially generates a compound of formula (II), or a salt thereof, wherein the newly-formed amino group has (R) or (S) stereochemistry.

In certain embodiments, the enzyme is an omega amine transaminase, a broad-range transaminase, a glutamate-pyruvate transaminase or a glutamate-oxaloacetic transaminase.

In certain embodiments, the enzyme is an omega amine transaminase.

In certain embodiments, the omega amine transaminase is selected from the group consisting of ATA-101, ATA-102, ATA-103, ATA-104, ATA-105, ATA-106, ATA-107, ATA-108, ATA-109, ATA-110, ATA-113, ATA-114, ATA-115, ATA-116, ATA-117, ATA-124, an omega amine transaminase from Chromobacterium violaceum, an omega amine transaminase from Alcaligenes denitrificans, an omega amine transaminase from Arthrobactercitreus, an omega amine transaminase from Klebsiella pneumoniae, an omega amine transaminase from Bacillus thuringiensis, an omega amine transaminase from Bacillus cereus, and an omega amine transaminase from Vibrio fluvialis.

In certain embodiments, the amino donor molecule is an amine or a salt thereof. In certain embodiments, the amine is selected from pyridoxamine, methylbenzylamine, 2-aminobutane, propyl amine, isopropyl amine, 1,1,1-trifluoropropan-2-amine, 1,1,1,3,3,3-hexafluoropropan-2-amine, benzyl amine, 2-amino-1-butanol, 1-amino-1-phenylethane, 1-amino-1-(2-methoxy-5-fluorophenyl)ethane, 1-amino-1-phenylpropane, 1-amino-1-(4hydroxyphenyl)propane, 1-amino-1-(4-bromophenyl)propane, 1-amino-1-(4-nitrophenyl)propane, 1-phenyl-2-aminopropane, 1-(3-trifluoromethylphenyl)-2-aminopropane, 2-aminopropanol, 1-amino-1-phenylbutane, 1-phenyl-2-aminobutane, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminobutane, 1-phenyl-3-aminobutane, 1-(4-hydroxyphenyl)-3-aminobutane, 1-amino-1-(2-naphthyl)ethane, cis-2-methylcyclopentanamine, trans-2-methylcyclopentanamine, cis-3-methylcyclopentanamine, trans-3-methylcyclopentanamine, cis-2-ethylcyclopentanamine, trans-2-ethylcyclopentanamine, cis-3-ethylcyclopentanamine, trans-3-ethylcyclopentanamine, cis-2-methylcyclohexanamine, trans-2-methylcyclohexanamine, cis-3-methylcyclohexanamine, trans-3-methylcyclohexanamine, cis-2-ethylcyclohexanamine, trans-2-ethylcyclohexanamine, cis-3-ethylcyclohexanamine, trans-3-ethylcyclohexanamine, 1-aminotetralin, 2-aminotetralin, 2-amino-5-methoxytetralin, 1-aminoindane, 2-aminoindane, 2-amino-1-propanol, cis-1-amino-2-indanol, trans-1-amino-2-indanol, 1-amino-6-hydroxyindanamine, taurine, or a salt thereof.

In certain embodiments, the amino donor molecule is a chiral amino donor molecule. In certain embodiments, the chiral amino donor molecule is a chiral amine or salt thereof, e.g., an amine containing at least one asymmetric center. Exemplary chiral amines include, but are not limited to, (R)-methylbenzylamine, (S)-methylbenzylamine, (S)-2-aminobutane, (R)-2-aminobutane, (S)-1-aminoindane, (R)-1-aminoindane, (R)-1,1,1-trifluoropropan-2-amine, (S)-1,1,1-trifluoropropan-2-amine, (R)-2-amino-1-propanol, (S)-2-amino-1-propanol, (1R,2S)-cis-1-amino-2-indanol, (1R,2R)-trans-1-amino-2-indanol, 1-(R)-amino-6-hydroxyindanamine, 1-(S)-amino-6-hydroxyindanamine, (R)-2-amino-1-butanol, (S)-2-amino-1-butanol, (R)-1-amino-1-phenylethane, (S)-1-amino-1-phenylethane, (R)-1-amino-1-(2-methoxy-5-fluorophenyl)ethane, (S)-1-amino-1-(2-methoxy-5-fluorophenyl)ethane, (R)-1-amino-1-phenylpropane, (S)-1-amino-1-phenylpropane, (R)-1-amino-1-(4-hydroxyphenyl)-propane, (S)-1-amino-1-(4-hydroxyphenyl)-propane, (R)-1-amino-1-(4-bromophenyl)propane, (S)-1-amino-1-(4-bromophenyl)propane, (R)-1-amino-1-(4-nitrophenyl)propane, (S)-1-amino-1-(4-nitrophenyl)propane, (R)-1-phenyl-2-aminopropane, (S)-1-phenyl-2-aminopropane, (R)-1-(3-trifluoromethylphenyl)-2-aminopropane, (S)-1-(3-trifluoromethylphenyl)-2-aminopropane (R)-1-amino-1-phenylbutane, (S)-1-amino-1-phenylbutane, (R)-1-phenyl-2-aminobutane, (S)-1-phenyl-2-aminobutane, (R)-1-(2,5-di-methoxy-4-methylphenyl)-2-aminobutane, (S)-1-(2,5-di-methoxy-4-methylphenyl)-2-aminobutane, (R)-1-phenyl-3-aminobutane, (S)-1-phenyl-3-aminobutane, (R)-1-(4-hydroxyphenyl)-3-aminobutane, (S)-1-(4-hydroxyphenyl)-3-aminobutane, (R)-1-amino-1-(2-naphthyl)ethane, (S)-1-amino-1-(2-naphthyl)ethane (R)-1-aminotetralin, (S)-1-aminotetralin, (R)-2-aminotetralin, (S)-2-aminotetralin, (R)-2-amino-5-methoxytetralin, (S)-2-amino-5-methoxytetralin, (1R,2S)-cis-2-methylcyclopentanamine, (1S,2R)-cis-2-methylcyclopentanamine, (1R,2R)-trans-2-methylcyclopentanamine, (1S,2S)-trans-2-methylcyclopentanamine, (1R,3S)-cis-3-methylcyclopentanamine, (1S,3R)-cis-3-methylcyclopentanamine, (1R,3R)-trans-3-methylcyclopentanamine, (1S,3S)-trans-3-methylcyclopentanamine, (1R,2S)-cis-2-ethylcyclopentanamine, (1S,2R)-cis-2-ethylcyclopentanamine, (1R,2R)-trans-2-ethylcyclopentanamine, (1S,2S)-trans-2-ethylcyclopentanamine, (1R,3S)-cis-3-ethylcyclopentanamine, (1S,3R)-cis-3-ethylcyclopentanamine, (1R,3R)-trans-3-ethylcyclopentanamine, (1S,3S)-trans-3-ethylcyclopentanamine, (1R,2S)-cis-2-methylcyclohexanamine, (1S,2R)-cis-2-methylcyclohexanamine, (1R,2R)-trans-2-methylcyclohexanamine, (1S,2S)-trans-2-methylcyclohexanamine, (1R,3S)-cis-3-methylcyclohexanamine, (1S,3R)-cis-3-methylcyclohexanamine, (1R,3R)-trans-3-methylcyclohexanamine, (1S,3S)-trans-3-methylcyclohexanamine, (1R,2S)-cis-2-ethylcyclohexanamine, (1S,2R)-cis-2-ethylcyclohexanamine, (1R,2R)-trans-2-ethylcyclohexanamine, (1S,2S)-trans-2-ethylcyclohexanamine, (1R,3S)-cis-3-ethylcyclohexanamine, (1S,3R)-cis-3-ethylcyclohexanamine, (1R,3R)-trans-3-ethylcyclohexanamine, (1S,3S)-trans-3-ethylcyclohexanamine, or a salt thereof.

In certain embodiments, the amino donor molecule is an amino acid or a polypeptide thereof and/or salt thereof. In certain embodiments, the amino acid is selected from glycine, alanine, aspartic acid, phenylalanine, 2-aminopentanedioic acid, 3-aminobutyrate, γ-aminobutyrate, β-alanine, asparagine, cysteine, glutamic acid, glutamine, proline, selenocysteine, serine, tyrosine, arginine, histidine, ornithine, isoleucine, leucine, lysine, methionine, threonine, tryptophan, valine, and polypeptides thereof and/or salts thereof.

In certain embodiments, the chiral amino donor molecule is a chiral amino acid or a polypeptide thereof and/or a salt thereof, e.g., containing at least one asymmetric center. Exemplary chiral amino acids include, but are not limited to, (L)-alanine, (D)-alanine, (L)-aspartic acid, (D)-aspartic acid, (L)-phenylalanine, (D)-phenylalanine, (2S)-2-aminopentanedioic acid, (L)-asparagine, (D)-asparagine, (L)-cysteine, (D)-cysteine, (L)-glutamine, (D)-glutamine, (L)-glutamic acid, (D)-glutamic acid, (L)-proline, (D)-proline, (L)-selenocysteine, (D)-selenocysteine, (L)-serine, (D)-serine, (L)-tyrosine, (D)-tyrosine, (L)-arginine, (D)-arginine, (L)-histidine, (D)-histidine, (L)-isoleucine, (D)-isoleucine, (L)-leucine, (D)-leucine, (L)-lysine, (D)-lysine, (L)-methionine, (D)-methionine, (L)-threonine, (D)-threonine, (L)-tryptophan, (D)-tryptophan, (L)-valine, (D)-valine, (L)-ornithine, (D)-ornithine, (3R)-aminobutyrate, (3S)-aminobutyrate and polypeptides thereof and/or salts thereof.

In certain embodiments, the solution is a buffered solution. In certain embodiments, the buffered solution is a sodium phosphate buffered solution.

In certain embodiments, the pH of the solution is between about 5 and about 9, between about 5 and about 8, between about 6 and about 8, between about 7 and about 8, between about 7 and about 7.5, or between about 7.5 and about 8.

In certain embodiments, the pH is of the solution is less than about 9, less than about 8.5, or less than about 8. In certain embodiments, the pH of the solution is about 7. In certain embodiments, the pH of the solution is about 7.5. In certain embodiments, the pH of the solution is about 8.

In certain embodiments, the compound of formula (I) or a salt thereof and a compound of formula (II) or a salt thereof are selected from any set of compounds provided in Tables 1, 2, 3, 4 or 5.

In certain embodiments, the process further comprises contacting a compound of formula (II) or a salt thereof with a sulfonylating agent to provide a compound of formula (III):

embedded image

or a salt thereof,

wherein R²³is alkyl or aryl.

In certain embodiments, the sulfonylating agent is selected from benzenesulfonyl chloride, benzenesulfonyl anhydride, p-toluenesulfonyl chloride, p-toluenesulfonyl anhydride, methanesulfonyl chloride, and methanesulfonyl anhydride. In certain embodiments, the sulfonylating agent is methanesulfonyl chloride or methanesulfonyl anhydride, and R²³is —CH₃.

The details of additional or alternative embodiments are set forth in the accompanying Detailed Description and Examples as described below. Other features, objects, and advantages of the invention will be apparent from this description and from the claims.

Definitions

Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75^thEd., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5^thEdition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3^rdEdition, Cambridge University Press, Cambridge, 1987, each of which is incorporated herein by reference.

Certain compounds of the present invention comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. The compounds provided herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. In certain embodiments, the compounds of the invention are enantiopure compounds. In certain other embodiments, mixtures of stereoisomers are provided.

Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the cis or trans, or the E or Z isomer, unless otherwise indicated. The invention additionally encompasses the compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers, e.g., racemic mixtures of E/Z isomers or mixtures enriched in one E/Z isomer.

The terms “enantiomerically enriched,” “enantiomerically pure” and “non-racemic,” as used interchangeably herein, refer to compositions in which the percent by weight of one enantiomer is greater than the amount of that one enantiomer in a control mixture of the racemic composition (e.g., greater than 1:1 by weight). For example, an enantiomerically enriched preparation of the (S)-enantiomer, means a preparation of the compound having greater than 50% by weight of the (S)-enantiomer relative to the (R)-enantiomer, more preferably at least 75% by weight, and even more preferably at least 80% by weight. In some embodiments, the enrichment can be much greater than 80% by weight, providing a “substantially enantiomerically enriched,” “substantially enantiomerically pure” or a “substantially non-racemic” preparation, which refers to preparations of compositions which have at least 85% by weight of one enantiomer relative to other enantiomer, more preferably at least 90% by weight, and even more preferably at least 95% by weight. Enantiomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred enantiomers can be prepared by asymmetric syntheses. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, N Y, 1962); and Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, Ind. 1972), each of which is incorporated herein by reference.

Carbon atoms, unless otherwise specified, may optionally be substituted with one or more substituents. The number of substituents is typically limited by the number of available valences on the carbon atom, and may be substituted by replacement of one or more of the hydrogen atoms that would be available on the unsubstituted group. Suitable substituents are known in the art and include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkoxy, alkylthio, aryl, aryloxy, arylthio, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, heterocyclyl, halo, azido, hydroxyl, thio, amino, nitro, nitrile, imido, amido, carboxylic acid, aldehyde, carbonyl, ester, silyl, haloalkyl, haloalkoxy (e.g., perfluoroalkoxy such as —OCF₃), ═O, ═S, and the like.

When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, an alkyl group containing 1-6 carbon atoms (C_1-6alkyl) is intended to encompass, C₁, C₂, C₃, C₄, C₅, C₆, C_1-6, C_2-6, C_3-6, C_4-6, C_5-6, C_1-5, C_2-5, C_3-5, C_4-5, C_1-4, C_2-4, C_3-4, C_1-3, C_2-3, and C_1-2alkyl.

The term “alkyl,” as used herein, refers to saturated, straight- or branched-chain hydrocarbon radical containing between one and thirty carbon atoms. In certain embodiments, the alkyl group contains 1-20 carbon atoms. Alkyl groups, unless otherwise specified, may optionally be substituted with one or more substituents. In certain embodiments, the alkyl group contains 1-10 carbon atoms. In certain embodiments, the alkyl group contains 1-6 carbon atoms. In certain embodiments, the alkyl group contains 1-5 carbon atoms. In certain embodiments, the alkyl group contains 1-4 carbon atoms. In certain embodiments, the alkyl group contains 1-3 carbon atoms. In certain embodiments, the alkyl group contains 1-2 carbon atoms. In certain embodiments, the alkyl group contains 1 carbon atom. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like.

The term “alkenyl,” as used herein, denotes a straight- or branched-chain hydrocarbon radical having at least one carbon-carbon double bond by the removal of a single hydrogen atom, and containing between two and thirty carbon atoms. Alkenyl groups, unless otherwise specified, may optionally be substituted with one or more substituents. In certain embodiments, the alkenyl group contains 2-20 carbon atoms. In certain embodiments, the alkenyl group contains 2-10 carbon atoms. In certain embodiments, the alkenyl group contains 2-6 carbon atoms. In certain embodiments, the alkenyl group contains 2-5 carbon atoms. In certain embodiments, the alkenyl group contains 2-4 carbon atoms. In certain embodiment, the alkenyl group contains 2-3 carbon atoms. In certain embodiments, the alkenyl group contains 2 carbon atoms. Alkenyl groups include, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like.

The term “alkynyl,” as used herein, denotes a straight- or branched-chain hydrocarbon radical having at least one carbon-carbon triple bond by the removal of a single hydrogen atom, and containing between two and thirty carbon atoms. Alkynyl groups, unless otherwise specified, may optionally be substituted with one or more substituents. In certain embodiments, the alkynyl group contains 2-20 carbon atoms. In certain embodiments, the alkynyl group contains 2-10 carbon atoms. In certain embodiments, the alkynyl group contains 2-6 carbon atoms. In certain embodiments, the alkynyl group contains 2-5 carbon atoms. In certain embodiments, the alkynyl group contains 2-4 carbon atoms. In certain embodiments, the alkynyl group contains 2-3 carbon atoms. In certain embodiments, the alkynyl group contains 2 carbon atoms. Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.

The terms “cycloalkyl”, used alone or as part of a larger moiety, refer to a saturated monocyclic or bicyclic hydrocarbon ring system having from 3-15 carbon ring members. Cycloalkyl groups, unless otherwise specified, may optionally be substituted with one or more substituents. In certain embodiments, cycloalkyl groups contain 3-10 carbon ring members. In certain embodiments, cycloalkyl groups contain 3-9 carbon ring members. In certain embodiments, cycloalkyl groups contain 3-8 carbon ring members. In certain embodiments, cycloalkyl groups contain 3-7 carbon ring members. In certain embodiments, cycloalkyl groups contain 3-6 carbon ring members. In certain embodiments, cycloalkyl groups contain 3-5 carbon ring members. Cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The term “cycloalkyl” also includes saturated hydrocarbon ring systems that are fused to one or more aryl or heteroaryl rings, such as decahydronaphthyl or tetrahydronaphthyl, where the point of attachment is on the saturated hydrocarbon ring.

The term “aryl” used alone or as part of a larger moiety (as in “aralkyl”), refers to an aromatic monocyclic and bicyclic hydrocarbon ring system having a total of 6-10 carbon ring members. Aryl groups, unless otherwise specified, may optionally be substituted with one or more substituents. In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl”, as it is used herein, is a group in which an aryl ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl or tetrahydronaphthalyl, and the like, where the point of attachment is on the aryl ring.

The term “aralkyl” refers to an alkyl group, as defined herein, substituted by aryl group, as defined herein, wherein the point of attachment is on the alkyl group.

The term “heteroatom” refers to boron, phosphorus, selenium, nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of abasic nitrogen.

The terms “heteroaryl” used alone or as part of a larger moiety, e.g., “heteroaralkyl”, refer to an aromatic monocyclic or bicyclic hydrocarbon ring system having 5-10 ring atoms wherein the ring atoms comprise, in addition to carbon atoms, from one to five heteroatoms. Heteroaryl groups, unless otherwise specified, may optionally be substituted with one or more substituents. When used in reference to a ring atom of a heteroaryl group, the term “nitrogen” includes a substituted nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaryl ring is fused to one or more aryl, cycloalkyl or heterocycloalkyl rings, wherein the point of attachment is on the heteroaryl ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl.

The term “heteroaralkyl” refers to an alkyl group, as defined herein, substituted by a heteroaryl group, as defined herein, wherein the point of attachment is on the alkyl group.

As used herein, the terms “heterocycloalkyl” or “heterocyclyl” refer to a stable non-aromatic 5-7 membered monocyclic hydrocarbon or stable non-aromatic 7-10 membered bicyclic hydrocarbon that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more heteroatoms. Heterocycloalkyl or heterocyclyl groups, unless otherwise specified, may optionally be substituted with one or more substituents. When used in reference to a ring atom of a heterocycloalkyl group, the term “nitrogen” includes a substituted nitrogen. The point of attachment of a heterocycloalkyl group may be at any of its heteroatom or carbon ring atoms that results in a stable structure. Examples of heterocycloalkyl groups include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. “Heterocycloalkyl” also include groups in which the heterocycloalkyl ring is fused to one or more aryl, heteroaryl or cycloalkyl rings, such as indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocycloalkyl ring.

The term “unsaturated”, as used herein, means that a moiety has one or more double or triple bonds.

As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups, such as aryl or heteroaryl moieties, as defined herein.

The term “diradical” as used herein refers to an alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, and heteroaralkyl groups, as described herein, wherein 2 hydrogen atoms are removed to form a divalent moiety. Diradicals are typically end with a suffix of “-ene”. For example, alkyl diradicals are referred to as alkylenes (for example:

embedded image

and —(CR′₂)_x— wherein R′ is hydrogen or other substituent and x is 1, 2, 3, 4, 5 or 6); alkenyl diradicals are referred to as “alkenylenes”; alkynyl diradicals are referred to as “alkynylenes”; aryl and aralkyl diradicals are referred to as “arylenes” and “aralkylenes”, respectively (for example:

embedded image

heteroaryl and heteroaralkyl diradicals are referred to as “heteroarylenes” and “heteroaralkylenes”, respectively (for example:

embedded image

cycloalkyl diradicals are referred to as “cycloalkylenes”; heterocycloalkyl diradicals are referred to

as “heterocycloalkylenes”; and the like.

The terms “halo” and “halogen” as used herein refer to an atom selected from fluorine (fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), and iodine (iodo, —I).

As used herein, the term “haloalkyl” refers to an alkyl group, as described herein, wherein one or more of the hydrogen atoms of the alkyl group is replaced with one or more halogen atoms.

In certain embodiments, the haloalkyl group is a perhaloalkyl group, that is, having all of the hydrogen atoms of the alkyl group replaced with halogens (e.g., such as the perfluoroalkyl group —CF₃).

As used herein, the term “azido” refers to the group —N₃.

As used herein, the term “nitrile” refers to the group —CN.

As used herein, the term “nitro” refers to the group —NO₂.

As used herein, the term “hydroxyl” or “hydroxy” refers to the group —OH.

As used herein, the term “thiol” or “thio” refers to the group —SH.

As used herein, the term “carboxylic acid” refers to the group —CO₂H.

As used herein, the term “aldehyde” refers to the group —CHO.

As used herein, the term “alkoxy” refers to the group —OR′, wherein R′ is an alkyl, alkenyl or alkynyl group, as defined herein.

As used herein, the term “aryloxy” refers to the group —OR′, wherein each R′ is an aryl or heteroaryl group, as defined herein.

As used herein, the term “alkylthio” or “alkylthiooxy” refers to the group —SR′, wherein each R′ is, independently, a carbon moiety, such as, for example, an alkyl, alkenyl, or alkynyl group, as defined herein.

As used herein, the term “arylthio” refers to the group —SR′, wherein each R′ is an aryl or heteroaryl group, as defined herein.

As used herein, the term “amino” refers to the group —NR′₂, wherein each R′ is, independently, hydrogen, a carbon moiety, such as, for example, an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, as defined herein, or two R′ groups together with the nitrogen atom to which they are bound form a 5-8 membered ring.

As used herein, the term “carbonyl” refers to the group —C(═O)R′, wherein R′ is, independently, a carbon moiety, such as, for example, an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, as defined herein.

As used herein, the term “ester” refers to the group —C(═O)OR′ or —OC(═O)R′ wherein each R′ is, independently, a carbon moiety, such as, for example, an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, as defined herein.

As used herein, the term “amide” or “amido” refers to the group —C(═O)N(R′)₂or —NR′C(═O)R′ wherein each R′ is, independently, hydrogen or a carbon moiety, such as, for example, an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, as defined herein, or two R′ groups together with the nitrogen atom to which they are bound form a 5-8 membered ring.

As used herein, the term “imide” or “imido” refers to the group —C(═NR′)N(R′)₂or —NR′C(═NR′)R′ wherein each R′ is, independently, hydrogen or a carbon moiety, such as, for example, an alkyl, alkenyl, alkynyl, aryl or heteroaryl group, as defined herein, or wherein two R′ groups together with the nitrogen atom to which they are bound form a 5-8 membered ring.

As used herein “silyl” refers to the group —Si(R′)₃wherein R′ is a carbon moiety, such as, for example, an alkyl, alkenyl, alkynyl, aryl or heteroaryl group.

The term “salt” refers to inorganic and organic acid addition salts of compounds of the present invention. Non-limiting examples of representative salts include salts derived from suitable inorganic and organic acids, e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other acid addition salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like (see, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66:1-19, incorporated herein by reference).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the chemical synthesis of IPI-926 in six steps from a ketone starting material as described in Tremblay et al., “Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)” J. Med. Chem. (2009) 52:4400-4418. The inventive transamination method shortens this route by at least three steps.

FIGS. 2A-B depict two types of enzymatic transaminations. FIG. 2A depicts the L-alanine dehydrogenase (LADH)/formate dehydrogenase (FDH) promoted transamination. FIG. 2B depicts the lactate dehydrogenase (LDH)/Glucose dehydrogenase (GDH) promoted transamination.

DETAILED DESCRIPTION

Provided is a process for preparing a compound of formula (II):

embedded image

or a salt thereof;

from a compound of formula (I):

embedded image

or a salt thereof;

wherein:

R¹is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, —OR¹⁶, —C(O)R¹⁶, —CO₂R¹⁶, —SO₂R¹⁶, —C(O)N(R¹⁷)(R¹⁷), —[C(R¹⁶)₂]_q—R¹⁶, —[(W)—N(R¹⁷)C(O)]_qR¹⁶, —[(W)—C(O)]_qR¹⁶, —[(W)—C(O)O]_qR¹⁶, —[(W)—OC(O)]_qR¹⁶, —[(W)—SO₂]_qR¹⁶, —[(W)N(R¹⁷)SO₂]_qR¹⁶, —[(W)—C(O)N(R¹⁷)]_qR¹⁷, —[(W)—O]_qR¹⁶, —[(W)—N(R¹⁷)]_qR¹⁶, or [(W)—S]_qR¹⁶; wherein W is a diradical and q is 1, 2, 3, 4, 5, or 6;

each R²and R³is, independently, H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, halo, —OR¹⁶, —OR¹⁶, —N(R¹⁷)₂, or —SR¹⁶,

or R²and R³taken together form a double bond or form a group

embedded image

wherein Z is NR¹⁷, O, or C(R¹⁸)₂;

R⁴is independently H, halo, —OR¹⁶, —N(R¹⁷)₂, or —SR¹⁶;

each R⁵and R⁶, is, independently, H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, halo, —OR¹⁶, —N(R¹⁷)₂, or —SR¹⁶;

or R⁵and R⁶taken together with the carbon to which they are bonded, form C═O, C═S, C═N—OR¹⁷, C═N—R¹⁷, C═N—N(R¹⁷)₂, or form an optionally substituted 3-8 membered ring;

each R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹²and R¹³is, independently, H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, halo, —OR¹⁶, —N(R¹⁷)₂, or —SR¹⁶;

or R¹⁰and R¹¹taken together, or R¹¹and R¹²taken together, form a double bond or form a group

embedded image

wherein Z is NR¹⁷, O, or C(R¹⁸)₂;

each R¹⁴and R¹⁵is, independently, H, halo, —OR⁶, —N(R¹⁷)₂, or —SR¹⁶;

or R¹⁴and R′ taken together with the carbon to which they are bonded, form C═O or C═S;

X is a bond or the group —C(R¹⁹)₂—; wherein each R¹⁹is, independently, H, alkyl, aralkyl, halo, —CN, —OR¹⁶, or —N(R¹⁷)₂;

R¹⁶is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl or —[C(R²⁰)₂]_p—R²wherein p is 0-6; or any two occurrences of R¹⁶on the same substituent are taken together to form a 4-8 membered optionally substituted ring;

R¹⁷is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, —C(═O)R²⁰, —C(═O)OR²⁰, —SO₂R²⁰, —C(═O)N(R²⁰)₂, or —[C(R²⁰)₂]_p—R²wherein p is 0-6; or any two occurrences of R¹⁷on the same substituent are taken together to form a 4-8 membered optionally substituted ring;

R¹⁸is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, halo, —CN, —OR²⁰, —OSi(R²⁰)₃, —C(═O)R²⁰, —C(═O)OR²⁰, —SO₂R²⁰, or —C(═O)N(R²⁰)₂;

R²⁰is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; or any two occurrences of R²⁰on the same substituent are taken together to form a 4-8 membered optionally substituted ring;

R²¹is —OR²², —N(R²²)C(═O)R²², —N(R²²)C(═O)OR²², —N(R²²)SO₂(R²²), —C(═O)R²²N(R²²)₂, —OC(═O)R²²N(R²²)(R²²), —SO₂N(R²²)(R²²), —N(R²²)(R²²), —C(═O)OR²², —C(═O)N(OH)(R²²), —OS(O)₂OR²², —S(O)₂₀R²², —OP(═O)(OR²²)(OR²²), —N(R²²)P(O)(OR²²)(OR²²), or —P(═O)(OR²²)(OR²²); and

R²²is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl; or any two occurrences of R²²on the same substituent are taken together to form a 4-8 membered optionally substituted ring;

In certain embodiments, R¹is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, haloalkyl, —OR¹⁶, —C(O)R¹⁶, —CO₂R¹⁶, —SO₂R¹⁶, C(O)N(R¹⁷)(R¹⁷), or —[C(R¹⁶)₂]_q—R⁶. In certain embodiments, R¹is H, aralkyl, —C(O)R¹⁶, CO₂R¹⁶, —SO₂R¹⁶or —C(O)N(R¹⁷)(R¹⁷). In certain embodiments, R¹is H, aralkyl or —CO₂R¹⁶.

In certain embodiments, R¹is H.

In certain embodiments, R¹is aralkyl.

In certain embodiments, R¹is —CO₂R¹⁶. In certain embodiments, R¹is —CO₂R¹⁶and R¹⁶is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl or heteroaralkyl. In certain embodiments, R¹is a -Boc group (e.g., wherein R¹is —CO₂R¹⁶and R¹⁶is t-butyl). In certain embodiments, R¹is a -CBz group (e.g., wherein R¹is —CO₂R¹⁶and R¹⁶is benzyl).

In certain embodiments, R²and R³taken together form a double bond.

In certain embodiments, R²and R³form a group:

embedded image

wherein Z is —NR¹⁷—, —O—, or —C(R¹⁸)₂—. In certain embodiments, Z is —C(R¹⁸)₂—. In certain embodiments, Z is —CH₂—.

In certain embodiments, X is a bond. For example, in certain embodiments, wherein R²and R³are taken together form a double bond, or wherein R²and R³form a group:

embedded image

and Z is —NR¹⁷—, —O—, or —C(R¹⁸)₂—, then X is a bond.

In certain embodiments, X is the group —C(R¹⁹)₂—. In certain embodiments, R¹⁹is H, e.g., wherein X is —CH₂—.

In certain embodiments, wherein R²and R³are taken together form a double bond, then X is the group —C(R¹⁹)₂—. In certain embodiments, wherein R²and R³are taken together form a double bond, then X is the group —CH₂—.

In certain embodiments, R⁴is H.

In certain embodiments, each R⁵and R⁶, is, independently, H, or R⁵and R⁶taken together, along with the carbon to which they are bonded, form C═O. In certain embodiments, each of R⁵and R⁶is independently H. In certain embodiments, R⁵and R⁶taken together with the carbon to which they are bonded form C═O.

In certain embodiments, R⁷and R⁸are each H.

In certain embodiments, R⁹and R¹⁰are each H.

In certain embodiments, R¹¹is a H.

In certain embodiments, R¹²and R¹³are each H.

In certain embodiments, R¹⁴and R¹⁰are each H.

In certain embodiments, each of R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴and R¹⁵is H.

In certain embodiments, R⁹is H and R¹⁰and R¹¹taken together form a double bond.

In certain embodiments, R¹³is H, and R¹¹and R¹²taken together form a double bond.

In certain embodiments, the compound of formula (I) is a compound of the formula (I-AA):

embedded image

or salt thereof,

and the compound of formula (II) is a compound of the formula (II-AA):

embedded image

or salt thereof,

wherein R¹, R², R³, R⁵, R⁶, R¹⁰, R¹¹, R¹²and X are as defined herein.

In certain embodiments, the compound of formula (I) is a compound of the formula (I-BB):

embedded image

or salt thereof,

and the compound of formula (II) is a compound of the formula (II-BB):

embedded image

or salt thereof,

wherein R¹, R₂, R³, R⁵, R⁶and X are as defined herein.

In certain embodiments, the compound of formula (I) is a compound of the formula (I-CC):

embedded image

or salt thereof,

and the compound of formula (II) is a compound of the formula (II-CC):

embedded image

or salt thereof,

wherein R¹and X are as defined herein.

Exemplary compounds of formula (I) are provided in U.S. Pat. No. 7,230,004, U.S. Pat. No. 7,407,967, U.S. Publication No. 20080293754, and U.S. Publication No. 20090012109, each of which is incorporated herein by reference in their entirety.

In certain embodiments, the compound of formula (I) or a salt thereof, and a compound of formula (II) or a salt thereof, are selected from the set of compounds, or salts thereof, provided in Tables 1, 2, 3 and 4, and wherein R¹is as defined above and herein:

TABLE 1

Compound of formula (I)

embedded image

(I-a)

(I-b)

(I-c)

(I-d)

(I-e)

(I-f)

Compound of formula (II)

embedded image

(II-a)

(II-b)

(II-c)

(II-d)

(II-e)

(II-f)

TABLE 2

Compound of formula (I)

embedded image

(I-g)

(I-h)

(I-i)

(I-j)

(I-k)

(I-l)

Compound of formula (II)

embedded image

(II-g)

(II-h)

(II-i)

(II-j)

(II-k)

(II-l)

TABLE 3

Compound of formula (I)

embedded image

(I-m)

(I-n)

(I-o)

(I-p)

(I-q)

(I-r)

Compound of formula (II)

embedded image

(II-m)

(II-n)

(II-o)

(II-p)

(II-q)

(II-r)

TABLE 4

Compound of formula (I)

embedded image

(I-s)

(I-t)

(I-u)

(I-v)

(I-w)

(I-x)

Compound of formula (II)

embedded image

(II-s)

(II-t)

(II-u)

(II-v)

(II-w)

(II-x)

In certain embodiments, R¹is H.

In certain embodiments, R¹is aralkyl.

In certain embodiments, R¹is —CO₂R¹⁶. In certain embodiments, R¹is —CO₂R¹⁶and R¹⁶is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl or heteroaralkyl. In certain embodiments, R¹is a -Boc group (e.g., wherein R¹is —CO₂R⁶and R¹⁶is t-butyl). In certain embodiments, R¹is a -CBz group (e.g., wherein R¹is —CO₂R¹⁶and R¹⁶is benzyl).

In certain embodiments, the process preferentially generates a compound of formula (II), or a salt thereof, from a compound of formula (I), or salt thereof, wherein the newly-formed amino group provided in formula (II) has (R) or (S) stereochemistry.

For example, in certain embodiments, the process preferentially generates a compound of formula (II), or salt thereof, wherein the newly-formed amino group has (S) stereochemistry, e.g., a compound of the formula (S)-(II):

embedded image

or a salt thereof,

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵and X are as defined herein.

In certain embodiments, the process preferentially generates a compound of formula (II), or salt thereof, wherein the newly-formed amino group has (R) stereochemistry, e.g., a compound of the formula (R)-(II):

embedded image

or a salt thereof,

wherein R¹, R², R³, R⁴, R⁵, R⁶, R¹⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵and X are as defined herein.

As used herein, “preferentially generates” refers to the production of one stereoisomer of a compound of formula (II) in excess over the other stereoisomer. In certain embodiments, the process preferentially generates a compound of formula (II), or a salt thereof, wherein the newly-formed amino group has (R) or (S) stereochemistry, in greater than 40% diastereomeric excess (de), greater than 50% de, greater than 60% de, greater than 70% de, greater than 75% de, greater than 80% de, greater than 85% de, greater than 90% de, greater than 95% de, greater than 98% de, or greater than 99% de, as determined by HPLC.

In a preferred embodiment, the process preferentially generates a compound of formula (II), or salt thereof, wherein the newly-formed amino group has (R) stereochemistry.

For example, in certain embodiments, the compound of formula (I) is of the formula (I-AA):

embedded image

or salt thereof,

and the compound of formula (II) is of the formula (R)-(II-AA):

embedded image

or salt thereof,

wherein R¹, R², R³, R⁵, R⁶, R, R¹¹, R¹²and X are as defined herein.

In certain embodiments, the compound of formula (I) is of the formula (I-BB):

embedded image

or salt thereof,

and the compound of formula (II) is of the formula (R)-(II-BB):

embedded image

or salt thereof,

wherein R¹, R², R³, R⁵, R⁶and X are as defined herein.

In certain embodiments, the compound of formula (I) is of the formula (I-CC):

embedded image

or salt thereof,

and the compound of formula (II) is of the formula (R)-(II-CC):

embedded image

or salt thereof,

wherein R¹and X are as defined herein.

In another preferred embodiment, the compound of formulae (I) and (II) are selected from the set of compounds, or salts thereof, provided in Table 1.

In certain preferred embodiments, the process preferentially generates a compound of formula (II) of Table 1, or salt thereof, wherein the newly-formed amino group has (R) stereochemistry.

For example, in certain embodiments, the compound of formulae (I) and (II) are selected from a set of compounds, or salts thereof, provided in Table 5, wherein the newly-formed amino group of the compound of formula (II) has (R) stereochemistry:

TABLE 5

Compound of formula (I)

embedded image

(I-a)

(I-b)

(I-c)

(I-d)

(I-e)

(I-f)

Compound of formula (II)

embedded image

(R)- (II-a)

embedded image

(R)- (II-b)

embedded image

(R)- (II-c)

embedded image

(R)- (II-d)

embedded image

(R)- (II-e)

embedded image

(R)- (II-f)

In certain embodiments, the compound of formula (I) is a compound of formula (I-a):

embedded image

or salt thereof,

and the compound of formula (II) is a compound of formula (R)-(II-a):

embedded image

or a salt thereof,

wherein R¹is as defined herein.

In certain embodiments, R¹is H.

In certain embodiments, R¹is aralkyl.

Masked Ketones

In certain embodiments, the compound of formula (I) is a masked ketone. In this context, a “masked ketone” refers to a chemically modified compound of formula (I) or salt thereof containing a functional group which is transformed in situ (e.g., by hydrolysis) to the ketone.

Exemplary masked ketones include, but are not limited to, aminals and hemiaminals (see, for example, Vogel et al., J. Org. Chem. (2004) 69:4487-4491; Reeder and Meyers, Tetrahedron Letters (1999) 40:3115-3118, each of which is incorporated herein by reference), acetals and hemiacetals (see, for example, Boyce et al., Bioorg. Med. Chem. Lett. (2008) 18:5771-5773, incorporated herein by reference), hydrates (see, for example, Silverman et al., J. Med. Chem. (1987) 31:1566-1570, incorporated herein by reference), imines (see, for example, Hine et al., J. Am. Chem. Soc. (1970) 92:5194-5199, incorporated herein by reference), oximes (see, for example, Sha et al., J. Am. Chem. Soc. (2006) 128:9687-9692, incorporated herein by reference), thiocarbonyls (see, for example, Kalm, J. Chem. Soc. (1961) 2925-2929, incorporated herein by reference), thioacetals and thiohemiacetals (see, for example Ogura et al., Tetrahedron Letters (1986) 27:3665-3668, incorporated herein by reference), enol ethers (see for example, Manis and Rathke, J. Org. Chem. (1981) 46:5348-5351, incorporated herein by reference), and salts thereof.

For example, provided is a process for preparing a compound of formula (II):

embedded image

or a salt thereof;

from a masked ketone of a compound of formula (I):

embedded image

or salt thereof;

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵and X are as defined herein;

the process comprising contacting a masked ketone of a compound of formula (I) or a salt thereof, an amino donor molecule, and an amine transaminase enzyme in a solution to provide a compound of formula (II) or a salt thereof.

In certain embodiments, a compound of formula (I) is a masked ketone having the formula (I-DD):

embedded image

or a salt thereof,

wherein:

R²⁴and R²⁵are selected from —OR²⁶, —SR²⁶, and —N(R²⁶)₂,

- or R²⁴and R²⁵are taken together to form the group ═S, ═N—R²⁶, or ═N—OR²⁶,
- or R²⁴is —OR²⁷or —O(C═O)R²⁷and R²⁵and R⁸or R²⁵and R⁹are taken together to form a bond;

R²⁶is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, —C(═O)R²⁷, —C(═O)OR²⁷or —C(═O)N(R²⁸)₂, or any two occurrences of R²⁶are taken together to form a 4-8 membered optionally substituted ring;

R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; and

R²⁸is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; or any two occurrences of R²⁸on the same substituent are taken together to form a 4-8 membered optionally substituted ring.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a hydrate, an acetal or a hemiacetal.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a hydrate, an acetal or a hemiacetal of the formula (I-EE):

embedded image

or a salt thereof,

wherein:

R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; and

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a aminal or hemiaminal.

In certain embodiments, a compound of formula (I-DD), or a salt thereof, is a aminal or hemiaminal of the formula (I-FF):

embedded image

or a salt thereof,

wherein:

R²⁵is —OR²⁶or —N(R²⁶)₂;

R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; and

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a thioacetal or thiohemiacetal.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a thioacetal or thiohemiacetal of the formula (I-GG):

embedded image

or a salt thereof,

wherein:

R²⁵is —OR²⁶or —SR²⁶;

R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; and

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is an imine.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is an imine of the formula (I-HH):

embedded image

or a salt thereof,

wherein:

R²⁶is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, —C(═O)R²⁷, —C(═O)OR²⁷or —C(═O)N(R²⁸)₂;

R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; and

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is an oxime.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is an oxime of the formula (I-JJ):

embedded image

or a salt thereof,

wherein:

R²⁶is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl, —C(═O)R²⁷, —C(═O)OR²⁷or —C(═O)N(R²⁸)₂;

R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl; and

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a thiocarbonyl.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is a thiocarbonyl of the formula (I-KK):

embedded image

or a salt thereof.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is an enol ether.

In certain embodiments, a compound of formula (I-DD) or a salt thereof, is an enol ether of the formulae (I-LL) or (I-MM):

embedded image

or a mixture thereof and/or a salt thereof,

wherein R²⁴is —OR²⁷or —O(C═O)R²⁷and R²⁷is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, or heteroaralkyl.

Amino Donor Molecule

An “amino donor molecule” is a compound having an —NH₂group which, during the course of the reaction, is transferred to the compound of formula (I). Amino donor molecules include both amines and amino acids.

In certain embodiments, the amino donor molecule is an amine or salt thereof (e.g., a primary amine). Exemplary amine include, but are not limited to, pyridoxamine, methylbenzylamine, 2-aminobutane, propyl amine, isopropyl amine, 1,1,1-trifluoropropan-2-amine, 1,1,1,3,3,3-hexafluoropropan-2-amine, benzyl amine, 2-amino-1-butanol, 1-amino-1-phenylethane, 1-amino-1-(2-methoxy-5-fluorophenyl)ethane, 1-amino-1-phenylpropane, 1-amino-1-(4hydroxyphenyl)propane, 1-amino-1-(4-bromophenyl)propane, 1-amino-1-(4-nitrophenyl)propane, 1-phenyl-2-aminopropane, 1-(3-trifluoromethylphenyl)-2-aminopropane, 2-aminopropanol, 1-amino-1-phenylbutane, 1-phenyl-2-aminobutane, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminobutane, 1-phenyl-3-aminobutane, 1-(4-hydroxyphenyl)-3-aminobutane, 1-amino-1-(2-naphthyl)ethane, cis-2-methylcyclopentanamine, trans-2-methylcyclopentanamine, cis-3-methylcyclopentanamine, trans-3-methylcyclopentanamine, cis-2-ethylcyclopentanamine, trans-2-ethylcyclopentanamine, cis-3-ethylcyclopentanamine, trans-3-ethylcyclopentanamine, cis-2-methylcyclohexanamine, trans-2-methylcyclohexanamine, cis-3-methylcyclohexanamine, trans-3-methylcyclohexanamine, cis-2-ethylcyclohexanamine, trans-2-ethylcyclohexanamine, cis-3-ethylcyclohexanamine, trans-3-ethylcyclohexanamine, 1-aminotetralin, 2-aminotetralin, 2-amino-5-methoxytetralin, 1-aminoindane, 2-aminoindane, 2-amino-1-propanol, cis-1-amino-2-indanol, trans-1-amino-2-indanol, 1-amino-6-hydroxyindanamine, taurine, and salts thereof.

In certain embodiments, the amino donor molecule is an amino acid or a polypeptide thereof and/or a salt thereof. A polypeptide, as used herein, refers to two or more amino acids joined by a peptide bond. In certain embodiments, the polypeptide is a dipeptide (e.g., two amino acids joined by a peptide bond).

In certain embodiments, the amino acid is selected from glycine, alanine, aspartic acid, phenylalanine, 2-aminopentanedioic acid, 3-aminobutyrate, γ-aminobutyrate, β-alanine, asparagine, cysteine, glutamic acid, glutamine, proline, selenocysteine, serine, tyrosine, arginine, histidine, ornithine, isoleucine, leucine, lysine, methionine, threonine, tryptophan, valine, and polypeptides thereof and/or salts thereof.

In certain embodiments, the amino donor molecule is a chiral amino donor molecule or a salt thereof, e.g., an amino donor molecule containing at least one asymmetric center. In certain embodiments, the amino group (—NH₂) to be transferred is attached to a chiral carbon. In certain embodiments, the chiral carbon has (R)-stereochemistry. In certain embodiments, the chiral carbon has (S)-stereochemistry.

In certain embodiments, the chiral amino donor molecule is a chiral amine or a salt thereof, e.g., an amine containing at least one asymmetric center. Exemplary chiral amines include, but are not limited to, (R)-methylbenzylamine, (S)-methylbenzylamine, (S)-2-aminobutane, (R)-2-aminobutane, (S)-1-aminoindane, (R)-1-aminoindane, (R)-1,1,1-trifluoropropan-2-amine, (S)-1,1,1-trifluoropropan-2-amine, (R)-2-amino-1-propanol, (S)-2-amino-1-propanol, (1R,2S)-cis-1-amino-2-indanol, (1R,2R)-trans-1-amino-2-indanol, 1-(R)-amino-6-hydroxyindanamine, 1-(S)-amino-6-hydroxyindanamine, (R)-2-amino-1-butanol, (S)-2-amino-1-butanol, (R)-1-amino-1-phenylethane, (S)-1-amino-1-phenylethane, (R)-1-amino-1-(2-methoxy-5-fluorophenyl)ethane, (S)-1-amino-1-(2-methoxy-5-fluorophenyl)ethane, (R)-1-amino-1-phenylpropane, (S)-1-amino-1-phenylpropane, (R)-1-amino-1-(4-hydroxyphenyl)-propane, (S)-1-amino-1-(4-hydroxyphenyl)-propane, (R)-1-amino-1-(4-bromophenyl)propane, (S)-1-amino-1-(4-bromophenyl)propane, (R)-1-amino-1-(4-nitrophenyl)propane, (S)-1-amino-1-(4-nitrophenyl)propane, (R)-1-phenyl-2-aminopropane, (S)-1-phenyl-2-aminopropane, (R)-1-(3-trifluoromethylphenyl)-2-aminopropane, (S)-1-(3-trifluoromethylphenyl)-2-aminopropane (R)-1-amino-1-phenylbutane, (S)-1-amino-1-phenylbutane, (R)-1-phenyl-2-aminobutane, (S)-1-phenyl-2-aminobutane, (R)-1-(2,5-di-methoxy-4-methylphenyl)-2-aminobutane, (S)-1-(2,5-di-methoxy-4-methylphenyl)-2-aminobutane, (R)-1-phenyl-3-aminobutane, (S)-1-phenyl-3-aminobutane, (R)-1-(4-hydroxyphenyl)-3-aminobutane, (S)-1-(4-hydroxyphenyl)-3-aminobutane, (R)-1-amino-1-(2-naphthyl)ethane, (S)-1-amino-1-(2-naphthyl)ethane (R)-1-aminotetralin, (S)-1-aminotetralin, (R)-2-aminotetralin, (S)-2-aminotetralin, (R)-2-amino-5-methoxytetralin, (S)-2-amino-5-methoxytetralin, (1R,2S)-cis-2-methylcyclopentanamine, (1S,2R)-cis-2-methylcyclopentanamine, (1R,2R)-trans-2-methylcyclopentanamine, (1S,2S)-trans-2-methylcyclopentanamine, (1R,3S)-cis-3-methylcyclopentanamine, (1S,3R)-cis-3-methylcyclopentanamine, (1R,3R)-trans-3-methylcyclopentanamine, (1S,3S)-trans-3-methylcyclopentanamine, (1R,2S)-cis-2-ethylcyclopentanamine, (1S,2R)-cis-2-ethylcyclopentanamine, (1R,2R)-trans-2-ethylcyclopentanamine, (1S,2S)-trans-2-ethylcyclopentanamine, (1R,3S)-cis-3-ethylcyclopentanamine, (1S,3R)-cis-3-ethylcyclopentanamine, (1R,3R)-trans-3-ethylcyclopentanamine, (1S,3S)-trans-3-ethylcyclopentanamine, (1R,2S)-cis-2-methylcyclohexanamine, (1S,2R)-cis-2-methylcyclohexanamine, (1R,2R)-trans-2-methylcyclohexanamine, (1S,2S)-trans-2-methylcyclohexanamine, (1R,3S)-cis-3-methylcyclohexanamine, (1S,3R)-cis-3-methylcyclohexanamine, (1R,3R)-trans-3-methylcyclohexanamine, (1S,3S)-trans-3-methylcyclohexanamine, (1R,2S)-cis-2-ethylcyclohexanamine, (1S,2R)-cis-2-ethylcyclohexanamine, (1R,2R)-trans-2-ethylcyclohexanamine, (1S,2S)-trans-2-ethylcyclohexanamine, (1R,3S)-cis-3-ethylcyclohexanamine, (1S,3R)-cis-3-ethylcyclohexanamine, (1R,3R)-trans-3-ethylcyclohexanamine, (1S,3S)-trans-3-ethylcyclohexanamine, and salts thereof.

In certain embodiments, the chiral amino donor molecule is (R)-methylbenzylamine or a salt thereof. In other embodiments, the chiral amino donor molecule is (S)-methylbenzylamine or a salt thereof.

In certain embodiments, the chiral amino donor molecule is (L)-alanine or a salt thereof.

In certain embodiments, the chiral amino donor molecule is (D)-alanine or a salt thereof.

In certain embodiments, the chiral amino donor molecule is (S)-1-aminoindane. In certain embodiments, the chiral amino donor molecule is (R)-1-aminoindane.

In certain embodiments, the process comprises contacting a compound of formula (I), a chiral amino donor molecule, and an amine transaminase enzyme in a solution to provide a compound of formula (II), or a salt thereof, with the newly-formed amino group having (S) stereochemistry.

In certain embodiments, the process comprises contacting a compound of formula (I), or a salt thereof, a chiral amino donor molecule, and an amine transaminase enzyme in a solution to provide a compound of formula (II), or a salt thereof, with the newly-formed amino group having (R) stereochemistry.

Amine Transaminase (ATA) Enzyme

An amine transaminase (ATA) enzyme catalyzes the transfer of the —NH₂group from the amino donor molecule to a compound having a ketone functional group, e.g., a compound of formula (I), in order to provide a compound of formula (II).

In certain embodiments, the amine transaminase enzyme preferentially generates a compound of formula (II), or a salt thereof, with the newly-formed amino group having (R) or (S) stereochemistry. As used herein, “preferentially generates” refers to the production of one stereoisomer of a compound of formula (II) in excess over the other stereoisomer.

In certain embodiments, the amine transaminase enzyme preferentially generates a compound of formula (II), or a salt thereof, with the newly-formed amino group having (R) stereochemistry.

In certain embodiments, the amine transaminase enzyme preferentially generates a compound of formula (II), or a salt thereof, with the newly-formed amino group having (S) stereochemistry.

In certain embodiments, the amine transaminase enzyme preferentially generates a compound of formula (II), or a salt thereof, with the newly-formed amino group having (R) or (S) stereochemistry, in greater than 40% diastereomeric excess (de), greater than 50% de, greater than 60% de, greater than 70% de, greater than 75% de, greater than 80% de, greater than 85% de, greater than 90% d e, greater than 95% d e, greater than 98% d e, or greater than 99% de, as determined by HPLC.

In certain embodiments, the amine transaminase enzyme preferentially generates an enantiomerically pure compound of formula (II), or salt thereof.

In certain embodiments, the amine transaminase enzyme is an omega amine transaminase enzyme, a broad-range transaminase, a glutamate-pyruvate transaminase or a glutamate-oxaloacetic transaminase.

In certain embodiments, the amine transaminase enzyme is an omega amine transaminase enzyme.

Exemplary omega amine transaminase enzymes include, but are not limited to, omega amine transaminase enzymes from Codexis, Inc. (Redwood City, Calif.), such as ATA-101, ATA-102, ATA-103, ATA-104, ATA-105, ATA-106, ATA-107, ATA-108, ATA-109, ATA-110, ATA-113, ATA-114, ATA-115, ATA-116, ATA-117 and ATA-124; omega amine transaminases from Vibrio fluvialis, Alcaligenes denitrificans, Klebsiella pneumoniae, or Bacillus thuringiensis, such as is described in WO 2007093372, incorporated herein by reference; omega amine transaminases from Chromobacterium violaceum, such as is described in Smithies et al., Tetrahedron Asymmetry (2009) 570-574, incorporated herein by reference, omega amine transaminases from Bacillus cereus, such as is described in Nakano et al., J. Biochem. (1977) 81:1375-1381, incorporated herein by reference, and omega amine transaminases from Arthrobactercitreus, such as described in Cassimjee et al., ChemComm (2010) 46:5569-5571, incorporated herein by reference.

Other suitable exemplary omega amine transaminases which may be used according to the present invention are described in Iwa-saki et al., Biotechnol. Lett. (2003) 25:1843-1846; Shin et al., Biotechnol. Bioeng. (1997) 55:348-358; Shin and Kim, Biosc. Biotechnol. Biochem. (2001) 65:1782-1788; Koszelewski et al., Trends in Biotechnology (2010) 28:324-332, and Shin and Kim, Biotechnol. Bioeng. (1998) 60:534-540, each of which is incorporated herein by reference.

Immobilization of the amine transaminase enzyme can also be effective to improve the stability of the enzyme which in turn will allow its re-use, thereby making the process more economical. Immobilization of the enzymes has been achieved by a simple adsorption onto a hydrophobic resin or by intermolecular covalent cross-linking of enzymes with a variety of functional groups or finally by incorporating enzymes into the lattice of a polymer matrix or a membrane. Covalent immobilization of the omega amine transaminase from Vibrio fluvialis JS17 has been reported by Lee and co-workers where the authors adsorb the enzyme on chitosan beads and subsequently cross linked with glutaraldehyde (Yi et al., Proc. Biochem. (2007) 42:895-898, incorporated herein by reference). The immobilized amine transaminase enzyme on chitosan beads retained ca. 77% of its activity after five consecutive reactions with the substrate indicating the utility of the process.

In certain embodiments, the omega amine transaminase enzyme is an amine transaminase enzyme from Codexis, Inc.

In certain embodiments, the omega amine transaminase enzyme is ATA-113.

In certain embodiments, the omega amine transaminase enzyme is ATA-117.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Vibrio fluvialis.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Alcaligenes denitrificans.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Arthrobactercitreus.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Klebsiella pneumoniae.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Bacillus thuringiensis.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Bacillus cereus.

In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Chromobacterium violaceum.

In certain embodiments, the omega amine transaminase enzyme is an immobilized omega amine transaminase enzyme.

Co-Factors

In certain embodiments, the process further comprises adding a co-factor to the solution. Co-factors include prosthetic groups which are bound to an enzyme during the enzymatic reaction, and co-enzymes which act to transfer chemical groups during the enzymatic reaction.

Exemplary co-factors include the prosthetic group pyridoxal phosphate (PLP) and co-enzymes such as L-alanine dehydrogenase (LADH), lactate dehydrogenase (LDH), nicotinamide adenine dinucleotide phosphate (NADPH), nicotinamide adenine dinucleotide (NAD), formate dehydrogenase (FDH) and glucose dehydrogenase (GDH).

In certain embodiments, the process further comprises adding the co-factor pyridoxal phosphate (PLP) to the solution.

In certain embodiments, the amine transaminase enzyme and the co-factor pyridoxal phosphate added to the solution are pre-complexed before contacting with the compound of formula I. In other embodiments, the amine transaminase (ATA) enzyme and pyridoxal phosphate added to the solution are not pre-complexed before contacting with the compound of formula I (i.e., each is individually added to the solution).

In certain embodiments, the process further comprises adding a co-enzyme to the solution.

In certain embodiments, the process further comprises adding one or more co-enzymes selected from L-alanine dehydrogenase (LADH), lactate dehydrogenase (LDH), nicotinamide adenine dinucleotide phosphate (NADPH), nicotinamide adenine dinucleotide (NAD), formate dehydrogenase (FDH), and glucose dehydrogenase (GDH) to the solution.

In certain embodiments, the process further comprises adding the co-enzyme LADH to the solution.

In certain embodiments, the process further comprises adding the co-enzyme FDH to the solution.

In certain embodiments, the process further comprises adding the co-enzyme NAD to the solution.

In certain embodiments, the process further comprises adding the co-enzyme LDH to the solution.

In certain embodiments, the process further comprises adding the co-enzyme GDH to the solution.

In certain embodiments, the process further comprises adding a mixture of LADH, FDH and NAD to the solution.

In certain embodiments, the process further comprises adding a mixture of co-enzymes LDH, GDH and NAD to the solution.

In certain embodiments, the process further comprises adding a sugar to the solution. In certain embodiments, the sugar is glucose.

In certain embodiments, process further comprises adding a pyruvate reductase mix to the solution. In certain embodiments, the process further comprises adding a mixture of co-enzymes LDH, GDH, NAD, and the sugar glucose (e.g., for example, pyruvate reductase mix PRM-102, available from Codexis, Inc.) to the solution.

In certain embodiments, the process further comprises adding ammonia or an ammonium salt to the solution. In certain embodiments, the ammonium salt is ammonium formate (NH₄CO₂H). Ammonium formate can be obtained in situ from the combination of formic acid and ammonia.

Other Reaction Conditions

In certain embodiments, the solution comprises an aqueous solution.

In certain embodiments, the aqueous solution is a buffered aqueous solution. Exemplary buffers include, but are not limited to, 3-{[tris(hydroxymethyl)methyl]amino}propanesulfonic acid (TAPS), N,N-bis(2-hydroxyethyl)glycine (Bicine), tris(hydroxymethyl)methylamine (Tris), N-tris(hydroxymethyl)methylglycine (Tricine), 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid (TES), 3-(N-morpholino)propanesulfonic acid (MOPS), piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), dimethylarsinic acid (Cacodylate), 2-(N-morpholino)ethanesulfonic acid (MES), carbonic acid, phosphate buffered saline (PBS), acetate, sodium phosphate, and salts thereof.

In certain embodiments, the buffered aqueous solution is a sodium phosphate buffered solution.

In certain embodiments, the solution further comprises a co-solvent. In certain embodiments, the co-solvent is an organic solvent.

In certain embodiments, the organic solvent is water miscible. In certain embodiments, the organic solvent is water immicible.

In certain embodiments, the solution is a monophasic system, e.g., comprising an aqueous solution and one or more water miscible organic solvents. Suitable water miscible organic solvents include, but are not limited to, organic alcohols (e.g., methanol (MeOH), ethanol (EtOH), isopropanol (iPrOH) and 2,2,2-trifluoroethanol (CF₃CH₂OH)), dimethylsulfoxide (DMSO), dimethylformamide (DMF), glycols (e.g., ethylene glycol and propylene glycol), and mixtures thereof.

In certain embodiments, the solution comprises an aqueous solution and an organic alcohol. In certain embodiments, the solution comprises an aqueous solution and methanol.

However, in other embodiments, the solution is a biphasic system, e.g., comprising an aqueous solution and one or more water immicible organic solvents. Suitable water immicible organic solvents include, but are not limited to, alkanes (e.g., hexane, heptane, perfluorohexane), esters (e.g., ethyl acetate (EtOAc), isopropyl acetate (iPrOAc)), ketones (e.g., cyclohexanone), ethers (e.g., 2-methyl tetrahydrofuran), and aromatic hydrocarbons (e.g., toluene, xylenes, benzene).

In certain embodiments, the temperature of the solution is at least about 20° C., at least about 25° C., at least about 30° C., or at least about 35° C. In certain embodiments, the temperature of the solution is between about 20° C. and about 50° C.

In certain embodiments, the process further comprises a resin. Adsorption of the ketone starting material (I) or the product amine (II) to the resin reduces their respective concentration in the reaction medium, and thus reduces their propensity to inhibit the enzyme. Exemplary resins include, but are not limited to, Amberlite™, Amberlyst™ and Dowex™ resins.

In certain embodiments, the process further comprises a solublizer such as a cyclodextrin or a surfactant. Exemplary cyclodextrins include, but are not limited to, β-cyclodextrins and γ-cyclodextrins. Exemplary surfactants include, but are not limited to sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, and/or combinations thereof.

In certain embodiments, the process further comprises a sulfate (e.g., for example, sodium bisulfate). For example, when benzylamine is used as the amino donor molecule, sodium bisulfate reacts with the by-product benzaldehyde to form an insoluble bisulfite adduct.

In certain embodiments, the process further comprises a dehydrogenase enzyme (e.g., a yeast alcohol dehydrogenase (YADH) such as from Saccharomyces cerevisiae). For example, when isopropyl amine is used as the amino donor molecule, a YADH enzyme converts the acetone by-product to isopropanol, thereby shifting the equilibrium and driving the reaction to completion (see Cassimjee et al., Chem Comm (2010) 46:5569-5571, incorporated herein by reference).

Additional Embodiments

In certain embodiments, provided is a process for preparing a compound of formula (R)-(II-a):

embedded image

or a salt thereof;

from a compound of formula (I-a):

embedded image

or a salt thereof;

wherein:

R¹is H, aralkyl, or -CO₂R¹⁶;

R¹⁶is H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaryl, heteroaralkyl or —[C(R²⁰)₂]_p—R²¹wherein p is 0-6;

R²¹is —OR²², —N(R²²)C(═O)R²², —N(R²²)C(═O)OR²², —N(R²²)SO₂(R²²), —C(═O)R²²N(R²²)₂, —OC(═O)R²²N(R²²)(R²²), —SO₂N(R²²)(R²²), —N(R²²)(R²²), —C(═)OR²², —C(═O)N(OH)(R²²), —OS(O)₂OR²², —S(O)₂OR²², —OP(═O)(OR²²)(OR²²), —N(R²²)P(O)(OR²²)(OR²²), or —P(═O)(OR²²)(OR²²); and

the process comprising contacting a compound of formula (I-a) or a salt thereof, an amino donor molecule, and an amine transaminase enzyme in a solution to provide a compound of formula (R)-(II-a) or a salt thereof.

In certain embodiments, R¹is H, aralkyl, or —CO₂R¹⁶.

In certain embodiments, R¹is H.

In certain embodiments, R¹is aralkyl.

In certain embodiments, the amino donor molecule is a chiral amino donor molecule. In certain embodiments, the chiral amino donor molecule is (R)-methylbenzylamine or a salt thereof. In other embodiments, the chiral amino donor molecule is (S)-methylbenzylamine or a salt thereof.

In certain embodiments, the chiral amino donor molecule is (L)-alanine or a salt thereof.

In certain embodiments, the chiral amino donor molecule is (D)-alanine or a salt thereof.

In certain embodiments, the amine transaminase enzyme is an omega amine transaminase enzyme. In certain embodiments, the omega amine transaminase enzyme is ATA-113 from Codexis, Inc. In certain embodiments, the omega amine transaminase enzyme is ATA-117 from Codexis, Inc. In certain embodiments, the omega amine transaminase enzyme is an omega amine transaminase from Vibrio fluvialis.

Additional Steps

In certain embodiments, the process further comprises contacting a compound of formula (II):

embedded image

or a salt thereof,

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵and X are as defined herein,

with a sulfonylating agent to provide a compound of formula (III):

embedded image

or a salt thereof,

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵and X are as defined herein, and

R²³is alkyl or aryl.

Exemplary sulfonylating agents include, but are not limited to, benzenesulfonyl chloride, benzenesulfonyl anhydride, p-toluenesulfonyl chloride, p-toluenesulfonyl anhydride, methanesulfonyl chloride, and methanesulfonyl anhydride.

In certain embodiments, the sulfonylating agent is benzenesulfonyl chloride or benzenesulfonyl anhydride, and R²³is benzenyl (i.e., —C₆H₅).

In certain embodiments, the sulfonylating agent is p-toluenesulfonyl chloride or p-toluenesulfonyl anhydride, and R²³is toluenyl (i.e., —C₆H₄(p-CH₃)).

In certain embodiments, the sulfonylating agent is methanesulfonyl chloride or methanesulfonyl anhydride, and R²³is methyl (i.e., —CH₃).

In certain embodiments, the compound of formula (II) is:

embedded image

or a salt thereof,

and the compound of formula (III) is:

embedded image

or a salt thereof,

wherein R¹and R²³are as defined herein.

In certain embodiments, the compound of formula (II) is:

embedded image

or a salt thereof,

and the compound of formula (III) is:

embedded image

or a salt thereof,

wherein R¹and R²³are as defined herein.

In certain embodiments, R¹is H.

In certain embodiments, R¹is aralkyl.

In certain embodiments, R¹is —CO₂R¹⁶.

In certain embodiments wherein R¹is aralkyl or —CO₂R¹⁶, the process further comprises deprotecting the compound of formula (III) wherein R¹is aralkyl or —CO₂R¹⁶to provide a compound of formula (III) wherein R¹is H. Exemplary deprotection methods include, but are not limited to, reducing conditions, such as hydrogenation.

For example, in certain embodiments, the process further comprises deprotecting the compound of formula (R)-(III-a):

embedded image

or salt thereof,

wherein R¹is aralkyl or —CO₂R¹⁶,

to provide a compound of formula (R)-(III-b):

embedded image

or salt thereof,

wherein R²³is as defined herein.

EXEMPLIFICATION

The present disclosure now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration and are not intended to limit the disclosure herein.

Enzymatic Transamination of Compound (I-a)

embedded image

Materials and Methods

Enzymes.

A mine transaminase enzymes were purchased from commercially available sources, stored at −20° C., and used as received: ATA-113 (Codexis, Redwood City, Calif.; Lot no. 104020902); ATA-117 (Codexis, Redwood City, Calif.; Lot no. 104020902); omega-transaminase from Vibrio fluvialis (Fluka; cat. no 08374); glutamate pyruvate transaminase (Fluka); broad range transaminase (Fluka).

Co-Enzymes.

Co-enzymes utilized during the investigation include: L-alanine dehydrogenase (LADH, Sigma, no. A7653-100 U), formate dehydrogenase (FDH, Codexis, FDH-101) and pyruvate reductase mix (PRM-102, Codexis), which is a mixture lactate dehydrogenase (LDH), glucose dehydrogenase (GDH), glucose and NAD⁺.

pH.

The following buffers were used during the investigation: 100 mM sodium phosphate buffer (pH 7; Fluka no. 82637); 20 mM sodium phosphate buffer (pH 7.5; Fluka, no. 82592); 20 mM sodium phosphate buffer (pH 8; Fluka, no. 82593).

HPLC Method 1.

Symmetry C18 column 4.6×150 mm; flow rate 1.5 mL/min; mobile phase A=0.1% TFA in water; mobile phase B=0.1% TFA in acetonitrile; 10 μL injection; 40° C. column temperature; detection wavelength=215 nm (all species). Retention time of compound (II-a) (R¹=H: S-(II-a)=5.9 min; R-(II-a), =6.8 min).

HPLC Method 1 Gradient:

Time (minutes)
% mobile phase A
% mobile phase B

0
90
10

1.0
90
10

10.0
40
60

11.0
5
95

12.0
5
95

13.0
90
10

15.0
90
10

HPLC Method 2.

XBridge C8 column 4.6×75 mm; flow rate 1.0 mL/min; mobile phase A=10 mM ammonium formate buffer, pH 3.8; mobile phase B=0.05% formic acid in acetonitrile; 5 μL injection; 40° C. column temperature; detection wavelength=215 nm (all species). Retention time of compound (II-a) (R¹=Bn: S-(II-a)=7.0 min; R-(II-a)=7.5 min).

HPLC Method 2 Gradient:

Time (minutes)
% mobile phase A
% mobile phase B

0
80
20

2
80
20

16
5
95

18
5
95

18.1
80
20

20
80
20

HPLC Method 3.

Eclipse XDB-C8 column 4.6×50 mm; flow rate 1.5 mL/min; mobile phase A=0.1% TFA in water; mobile phase B=0.1% TFA in acetonitrile; 10 μL injection; 40° C. column temperature; detection wavelength=215 nm (all species). Retention time of compound (II-a) (R¹=Cbz: S-(II-a)=6.0 min; R-(II-a)=6.1 min).

HPLC Method 3 Gradient:

Time (minutes)
% mobile phase A
% mobile phase B

0
70
30

2.0
70
30

8.0
0
100

10.0
0
100

12.0
70
30

15.0
70
30

General Experimental Methods

Method A:

Compound (I-a), a sodium phosphate buffered solution, 1 mM pyridoxal phosphate (PLP), an amine transaminase enzyme, an amino donor molecule, PRM-102 and, optionally, a co-solvent, were added to a vial. The vial was capped and the reaction stirred at 30° C. for 72 hours. The reaction mixture was then lyophilized and the residue was re-dissolved in methanol (2 mL). A 100 μL portion of the methanol solution was filtered and analyzed by HPLC. The results of Experiments 1-8 using Method A are summarized in Table 6.

Method B:

Compound (I-a), a sodium phosphate buffered solution, 1 mM pyridoxal phosphate (PLP), amine transaminase enzyme, D-alanine, ammonium formate (NH₄CO₂H), L-alanine dehydrogenase (LADH) solution (8.05 U/mL), formate dehydrogenase (FDH) solution (10 U/mL), NAD (1 mM) and a co-solvent were added to a vial. The vial was capped and the reaction stirred at 30° C. for 72 hours. The reaction mixture was then lyophilized and the residue was re-dissolved in methanol (2 mL). A 100 μL portion of the methanol solution was filtered and analyzed by HPLC. The results of Experiments 1-10 using Method B are summarized in Table 7.

Method C:

Compound (I-a), a sodium phosphate buffered solution, pyridoxal phosphate (PLP) (0.5 mM to 1 mM), an amine transaminase enzyme, an amino donor molecule, and, optionally, a co-solvent and PRM-102, were added to a vial. The vial was capped and the reaction stirred at 37° C. for 24 hours to about 6 days (144 hours). The reaction mixture was then lyophilized and the residue was re-dissolved in methanol (2 mL). A 100 μL portion of the methanol solution was filtered and analyzed by HPLC. The results of Experiments 1-28 using Method C are summarized in Table 8.

Method D:

Compound (I-a), a sodium phosphate buffered solution, pyridoxal phosphate (PLP) (0.5 mM), an amine transaminase enzyme, an amino donor molecule (5 equivalents), PRM-102, and, optionally, a co-solvent, were added to a vial. The vial was capped and the reaction stirred at 37° C. for 24 hours to about 7 days (168 hours). A 100 μL portion of the reaction mixture was diluted with 1 volume of MeOH and analyzed by HPLC. The results of Experiments 1-13 using Method D are summarized in Table 9.

Method E:

Compound (I-a), a sodium phosphate buffered solution, pyridoxal phosphate (PLP) (0.5 mM), an amine transaminase enzyme, L-alanine (5 equivalents), PRM-102, and methanol (10% v/v) were added to a vial. The vial was capped and the reaction stirred at 37° C. for 24 hours to about 7 days (168 hours). A 100 μL portion of the reaction mixture was diluted with 1 volume of MeOH and analyzed by HPLC. The results of Experiments 1-5 using Method E are summarized in Table 10.

Method F:

Compound (I-a), a sodium phosphate buffered solution (pH=7.5), pyridoxal phosphate (PLP) (0.5 mM), an amine transaminase enzyme, L-alanine (5 equivalents), PRM-102, and methanol (10% v/v) were added to a vial. The vial was capped and the reaction stirred at 37° C. for 24 hours to about 7 days (168 hours). The pH of the aqueous layer was monitored at the onset and during the course of the reaction and if necessary, it was readjusted to 7.5 using 0.1 M NaOH solution. A 100 μL portion of the reaction mixture was diluted with 1 volume of MeOH and analyzed by HPLC. The results of Experiments 1-9 using Method F are summarized in Table 11.

Method G:

Compound (I-a), a sodium phosphate buffered solution (pH=7.5), pyridoxal phosphate (PLP) (0.5 mM), an amine transaminase enzyme, L-alanine (5 equivalents), PRM-102, an additive (100% wt/wt) and methanol (10% v/v) were added to a vial. The vial was capped and the reaction stirred at 37° C. for 24 hours to about 7 days (168 hours). A 100 μL portion of the reaction mixture was diluted with 1 volume of MeOH and analyzed by HPLC. The results of Experiments 1-5 using Method G are summarized in Table 12.

Method H:

Compound (I-a), a sodium phosphate buffered solution (pH=7.5), pyridoxal phosphate (PLP) (0.5 mM), an amine transaminase enzyme, L-alanine (5 equivalents), PRM-102, a co-solvent (10 to 20% v/v) were added to a vial. The vial was capped and the reaction stirred at 37° C. for 24 hours to about 7 days (168 hours). A 100 μL portion of the reaction mixture was diluted with 1 volume of MeOH and analyzed by HPLC. The results of Experiments 1-12 using Method H are summarized in Table 13.

TABLE 6

Method A

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
pH
Co-solvent
(mM)
Enzyme
donor
(mg)
(hrs)
2
Conversion

1
6.5 mg
100 mM
7
MeOH
1
ATA-117
D-alanine
39
72
(S)
3%

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(4.5 mg)

citrate salt)

2
6.5 mg
100 mM
7
CF₃CH₂OH
1
ATA-117
D-alanine
39
72
—
n/a

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(4.5 mg)

citrate salt)

3
20 mg
100 mM
7
none
1
ATA-117
D-alanine
60
72
(S)
3%

(R¹= H,
(2 mL)

(3 mg)
(9.5 mg)

citrate salt)

4
20 mg
100 mM
7
MeOH
1
ATA-117
D-alanine
60
72
(S)
2%

(R¹= H,
(1.8 mL)

(0.2 mL)

(10 mg)
(11 mg)

citrate salt)

5
20 mg
100 mM
7
MeOH
1
broad-range
D-alanine
60
72
—
n/a

(R¹= H,
(1.8 mL)

(0.2 mL)

transaminase
(11 mg)

citrate salt)

(1.7 mg)

6
20 mg
100 mM
7
MeOH
1
glutamate
D-alanine
60
72
—
n/a

(R¹= H,
(1.8 mL)

(0.2 mL)

pyruvate
(11 mg)

citrate salt)

transaminase

(1 mg)

7
20 mg
100 mM
7
none
1
ATA-113
L-alanine
60
72
(S)
15%

(R¹= H,
(2 mL)

(10 mg)
(9.5 mg)

citrate salt)

8
20 mg
100 mM
7
MeOH
1
ATA-113
L-alanine
60
72
(S)
5%

(R¹= H,
(1.8 mL)

(0.2 mL)

(10 mg)
(11 mg)

citrate salt)

TABLE 7

Method B

PLP

NH₄CO₂H
FDH
LADH
NAD

(I-a)
Buffer
pH
co-solvent
(mM)
enzyme
donor
(mg)
(μL)
(μL)
(mM)
2
%

1
3.5 mg
100 mM
7
DMSO
1
ATA-117
D-alanine
4
25
10
1
—
n/a

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(9.5 mg)

citrate salt)

2
3.5 mg
100 mM
7
MeOH
1
ATA-117
D-alanine
4
25
10
1
(S)
1%

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(9.5 mg)

citrate salt)

3
3.5 mg
20 mM
7.5
DMSO
1
ATA-117
D-alanine
4
25
10
1
—
n/a

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(9.5 mg)

citrate salt)

4
3.5 mg
20 mM
7.5
MeOH
1
ATA-117
D-alanine
4
25
10
1
—
n/a

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(9.5 mg)

citrate salt)

5
6.5 mg
100 mM
7
CF₃CH₂OH
1
ATA-117
D-alanine
6
50
20
1
—
n/a

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(13 mg)

citrate salt)

6
6.5 mg
100 mM
7
MeOH
1
ATA-117
D-alanine
9
50
20
1
(S)
5%

(R¹= H,
(0.85 mL)

(0.15 mL)

(3 mg)
(22 mg)

citrate salt)

7
3.5 mg
100 mM
7
MeOH
1
ATA-113
D-alanine
4
22
8.8
1
(S)
8%

(R¹= H,
(0.85 mL)

(0.15 mL)

(1.3 mg)
(9.5 mg)

citrate salt)

8
3.5 mg
100 mM
7
DMSO
1
ATA-113
D-alanine
4
22
8.8
1
(S)
37%

(R¹= H,
(0.85 mL)

(0.15 mL)

(1.3 mg)
(9.5 mg)

citrate salt)

9
10 mg
100 mM
7
DMSO
1
ATA-113
D-alanine
40
216
86
1
(S)
12%

(R¹= H,
(8.5 mL)

(1.5 mL)

(13 mg)
(95 mg)

citrate salt)

10
3.5 mg
100 mM
7
DMSO
1
ATA-113
D-alanine
5
22
8.8
1
(S)
10%

(R¹= H,
(0.85 mL)

(1.3 mL);

(1.3 mg)
(12 mg)

citrate salt)

Et₂O

(0.2 mL)

TABLE 8

Method C

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
pH
Co-solvent
(mM)
Enzyme
donor
(mg)
(hrs)
2
Conversion

1
15 mg
100 mM
7
MeOH
1
ATA-117
D-alanine
60
24
(S)
2%

(R¹= H)
(1.8 mL)

(0.2 mL)

(10 mg)
(13 mg)

2
15 mg
100 mM
7
MeOH
1
ATA-113
L-alanine
60
24
(S)
10%

(R¹= H)
(1.8 mL)

(0.2 mL)

(10 mg)
(13 mg)

3
1 mg
20 mM
7.5
MeOH
0.5
ATA-113
(S)-methyl benzyl
none
72
(S)
9%

(R¹= H)
(1.2 mL)

(0.12 mL)

(2 mg)
amine

(1.4 μL)

4
1 mg
20 mM
7.5
MeOH
0.5
ATA-113
(S)-methyl benzyl
30
72
(S)
41%

(R¹= H)
(1.2 mL)

(0.12 mL)

(2 mg)
amine

(1.4 μL)

5
8.5 mg
20 mM
7.5
MeOH
1
ATA-113
(S)-methyl benzyl
300
72
(S)
42%

(R¹= H)
(10 mL)

(1 mL)

(20 mg)
amine

(13 μL)

6
1 mg
20 mM
7.5
MeOH
0.5
ATA-117
(S)-methyl benzyl
none
72
—
n/a

(R¹= H)
(1.2 mL)

(0.12 mL)

(2 mg)
amine

(1.4 μL)

7
1 mg
20 mM
7.5
MeOH
0.5
ATA-117
(S)-methyl benzyl
30
72
—
n/a

(R¹= H)
(1.2 mL)

(0.12 mL)

(2 mg)
amine

(1.4 μL)

8
1 mg
20 mM
7.5
MeOH
0.5
ATA-117
(S)-methyl benzyl
60
72
—
n/a

(R¹= H)
(1.2 mL)

(0.12 mL)

(4 mg)
amine

(1.4 μL)

9
8.5 mg
20 mM
7.5
MeOH
0.5
ATA-117
(S)-methyl benzyl
150
72
—
n/a

(R¹= H)
(10 mL)

(1 mL)

(10 mg)
amine

(13 μL)

10
8.5 mg
20 mM
8
MeOH
0.5
ATA-117
(S)-methyl benzyl
300
72
—
n/a

(R¹= H)
(9 mL)

(1 mL)

(20 mg)
amine

(13 μL)

11
6.4 mg
20 mM
8
MeOH
0.5
ATA-117
(S)-methyl benzyl
300
72
—
n/a

(R¹= H)
(9 mL)

(1 mL)

(20 mg)
amine

(13 μL)

12
4.3 mg
20 mM
8
MeOH
0.5
ATA-117
(S)-methyl benzyl
300
72
—
n/a

(R¹= H)
(9 mL)

(1 mL)

(20 mg)
amine

(13 μL)

13
2.1 mg
20 mM
8
MeOH
0.5
ATA-117
(S)-methyl benzyl
300
72
—
n/a

(R¹= H)
(9 mL)

(1 mL)

(20 mg)
amine

(13 μL)

14
1.6 mg
20 mM
7.5
none
1

Vibrio

(S)-methyl benzyl
none
72
(R)
2%

(R¹= H)
(1.2 mL)

fluvialis

amine

(55 μL)
(13 μL)

15
1 mg
20 mM
7.5
MeOH
0.5

Vibrio

(R)-methyl benzyl
none
72
(R)
10%

(R¹= H)
(1.2 mL)

(0.12 mL)

Fluvialis

amine

(100 μL)
(1.4 μL)

16
4.3 mg
20 mM
7.5
MeOH
0.5

Vibrio

(R)-methyl benzyl
140
72
(R)
15%

(R¹= H)
(4.95 mL)

(0.55 mL)

Fluvialis

amine

(155 μL)
(6.5 μL)

17
1.6 mg
20 mM
7.5
none
0.5

Vibrio

(S)-methyl benzyl
none
72
(R)
3%

(R¹= H)
(2 mL)

Fluvialis

amine

(100 μL)
(1.4 μL)

18
8.5 mg
20 mM
7.5
MeOH
0.5

Vibrio

(R)-methyl benzyl
none
72
(R)
10%

(R¹= H)
(10 mL)

(1 mL)

Fluvialis

amine

(100 μL)
(13 μL)

19
8.5 mg
20 mM
7.5
MeOH
0.5

Vibrio

(S)-methyl benzyl
none
72
(R)
10%

(R¹= H)
(10 mL)

(1 mL)

Fluvialis

amine

(310 μL)
(13 μL)

20
8.5 mg
20 mM
7.5
MeOH
0.5

Vibrio

(S)-methyl benzyl
275
72
(R)
10%

(R¹= H)
(10 mL)

(1 mL)

Fluvialis

amine

(310 μL)
(13 μL)

21
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

(R)-methyl benzyl
300
72
(R)
17%

(R¹= H,
(10 mL)

(1 mL)

Fluvialis

amine

citrate salt)

(310 μL)
(13 μL)

22
7 mg
20 mM
7.5
MeOH
0.5

Vibrio

(R)-methyl benzyl
150
144
(R)
28%

(R¹= H,
(5 mL)

(0.5 mL)

Fluvialis

amine

citrate salt)

(155 μL)
(7 μL)

23
5.5 mg
20 mM
7.5
EtOAc
1

Vibrio

(R)-methyl benzyl
150
72
—
n/a

(R¹= Bn)
(5 mL)

(0.5 mL)

Fluvialis

amine

(150 μL)
(7 μL)

24
3.5 mg
20 mM
7.5
cyclohexanone
1

Vibrio

(R)-methyl benzyl
150
72
—
n/a

(R¹= Bn)
(5 mL)

(0.5 mL)

Fluvialis

amine

(150 μL)
(7 μL)

25
8.5 mg
20 mM
7
MeOH
0.5
ATA-113
(S)-methyl benzyl
300
72
(S)
1.7%

(R¹= Bn)
(10 mL)

(1 mL)

(20 mg)
amine

(13 μL)

26
8.5 mg
20 mM
7
MeOH
0.5
ATA-113
(S)-methyl benzyl
300
72
(S)
2%

(R¹= CBz)
(10 mL)

(1 mL)

(20 mg)
amine

(13 μL)

27
8.5 mg
20 mM
7
MeOH
0.5
ATA-117
(S)-methyl benzyl
300
72
—
n/a

(R¹= Bn)
(10 mL)

(1 mL)

(20 mg)
amine

(13 μL)

28
8.5 mg
20 mM
7
MeOH
0.5
ATA-117
(S)-methyl benzyl
300
72
—
n/a

(R¹= Cbz)
(10 mL)

(1 mL)

(20 mg)
amine

(13 μL)

TABLE 9

Method D

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
pH
Co-solvent
(mM)
Enzyme
Donor (5 equiv.)
(mg)
(hrs)
2
Conversion

1
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
16.1%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

2
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

D-alanine
300 mg
168
(R)
12.7%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

3
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

R-Methylbenzylamine
300 mg
168
(R)
14.1%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

4
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

S-Methyl benzylamine
300 mg
168
(R)
7.6%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

5
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

2-aminoindane
300 mg
168
(R)
4.1%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

6
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

S-1-Aminoindane
300 mg
168
—
n/a

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

7
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

R-1-Aminoindane
300 mg
168
(R)
5.1%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

8
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

R-2-Amino-1-propanol
300 mg
168
(R)
3.8%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

9
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

S-2-Amino-1-propanol
300 mg
168
(R)
4.6%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

10
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

(1R, 2S)-cis-1-Amino-2-
300 mg
168
—
n/a

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

indanol

citrate salt)

(310 μL)

11
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

(1R, 2R)-trans-1-Amino-
300 mg
168
—
n/a

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

2-indanol

citrate salt)

(310 μL)

12
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

1-R-Amino-6-
300 mg
168
—
n/a

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

hydroxyindanamine

citrate salt)

(310 μL)

13
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

Isopropylamine
300 mg
168
(R)
8.4%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

citrate salt)

(310 μL)

TABLE 10

Method E

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
pH
Co-solvent
(mM)
Enzyme
donor
(mg)
(hrs)
2
Conversion

1
14 mg
20 mM
7.0
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
6.4%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

2
14 mg
20 mM
8.0
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
14.9%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

3
14 mg
20 mM
9.0
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
10.2%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

4
14 mg
100 mM
8.1
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
3.6%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

5
14 mg
100 mM
7.1
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
7.9%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

TABLE 11

Method F

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
pH
Co-solvent
(mM)
Enzyme
donor
(mg)
(hrs)
2
Conversion

1
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

D-alanine
300 mg
168
(R)
12.7%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

2
14 mg
20 mM
7.5
MeOH
none

Vibrio

D-alanine
300 mg
168
—
n/a

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

3
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
16.1%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

4
14 mg
20 mM
7.5
MeOH
none

Vibrio

L-alanine
300 mg
168
—
n/a

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

5
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
31%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(310 μL)

6
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
41.1%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(310 μL

on day 1,

155 μL

on day 4)

7
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
48.7%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis,
(10 mg)

citrate salt)

NEW BATCH

(310 μL

on day 1,

155 μL

on day 6)

8
45 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
8.6%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

NEW BATCH

(310 μL)

9
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
14.5%

(R¹= H,
(9 mL)

(1.0 mL)

Fluvialis,
(20 mg)

citrate salt)

NEW BATCH

(310 μL)

TABLE 12

Method G

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
Additives
Co-solvent
(mM)
Enzyme
donor
(mg)
(hrs)
2
Conversion

1
14 mg
20 mM
Amberlite
MeOH
0.5

Vibrio

L-alanine
300 mg
96
(R)
3.7%

(R¹= H,
(9 mL)
Resin
(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(100 wt %)

(310 μL)

2
14 mg
20 mM
Dowex Resin
MeOH
0.5

Vibrio

L-alanine
300 mg
96
—
n/a

(R¹= H,
(9 mL)
(100 wt %)
(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(310 μL)

3
14 mg
20 mM
β-Cyclodextrin
MeOH
0.5

Vibrio

L-alanine
300 mg
96
(R)
14.0

(R¹= H,
(9 mL)
(100 wt %)
(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(310 μL)

4
14 mg
20 mM
γ-Cyclodextrin
MeOH
0.5

Vibrio

L-alanine
300 mg
96
(R)
11.4

(R¹= H,
(9 mL)
(100 wt %)
(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(310 μL)

5
14 mg
20 mM
Sodium
MeOH
0.5

Vibrio

benzylamine
300 mg
96
—
n/a

(R¹= H,
(9 mL)
Bisulfite
(1.0 mL)

Fluvialis

(10 mg)

citrate salt)

(100 wt %)

(310 μL)

TABLE 13

Method H

PLP

Amine
PRM-102
Time

%

(I-a)
Buffer
pH
Co-solvent
(mM)
Enzyme
donor
(mg)
(hrs)
2
Conversion

1
14 mg
20 mM
7.5
none
0.5

Vibrio

L-alanine
300 mg
168
(R)
6.4%

(R¹= H,
(9 mL)

Fluvialis

(10 mg)

citrate salt)

(155 μL)

2
14 mg
20 mM
7.5
MeOH
0.5

Vibrio

L-alanine
300 mg
168
(R)
14.9%

(R¹= H)
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

(155 μL)

3
14 mg
20 mM
7.5
DMSO
0.5

Vibrio

L-alanine
300 mg
168
(R)
8.2%

(R¹= H)
(9 mL)

(1.0 mL)

Fluvialis

(10 mg)

(155 μL)

4
14 mg
100 mM
7.5
Heptane
0.5

Vibrio

L-alanine
300 mg
168
—
n/a

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

(10 mg)

(155 μL)

5
14 mg
100 mM
7.5
Heptane
0.5

Vibrio

R-Methyl
300 mg
168
—
n/a

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

benzylamine

(155 μL)

6
14 mg
100 mM
7.5
Toluene
0.5

Vibrio

L-alanine
300 mg
168
—
n/a

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

(10 mg)

(155 μL)

7
14 mg
100 mM
7.5
Toluene
0.5

Vibrio

R-Methy1
300 mg
168
—
n/a

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

benzylamine

(155 μL)

8
14 mg
100 mM
7.5
2-Methyl
0.5

Vibrio

L-alanine
300 mg
168
—
n/a

(R¹= H)
(9 mL)

tetrahydrofuran

Fluvialis

(10 mg)

(2.0 mL)

(155 μL)

9
14 mg
100 mM
7.5
2-Methyl
0.5

Vibrio

R-Methyl
300 mg
168
—
n/a

(R¹= H)
(9 mL)

tetrahydrofuran

Fluvialis

benzylamine

(2.0 mL)

(155 μL)

10
14 mg
100 mM
7.5
Ethylacetate
0.5

Vibrio

L-alanine
300 mg
168
(R)
12.9% (aq. layer)

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

(10 mg)

1.1% (organic

(155 μL)

layer)

11
14 mg
100 mM
7.5
Hexanes
0.5

Vibrio

L-alanine
300 mg
168
(R)
4.2% (aq. layer)

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

(10 mg)

1.6% (organic

(155 μL)

layer)

12
14 mg
100 mM
7.5
Perfluorohexane
0.5

Vibrio

L-alanine
300 mg
168
—
n/a

(R¹= H)
(9 mL)

(2.0 mL)

Fluvialis

(10 mg)

(155 μL)

Table Legend

PLP
pyridoxal phosphate

PRM 102
pyruvate reductase mix available from Codexis, Inc.

(R)
(R) isomer preferentially generated

(S)
(S) isomer preferentially generated

%
percent conversion of the preferred isomer as determined by

HPLC

n/a
no product detected by HPLC

Me
methyl, —CH₃

Bn
benzyl, —CH₂C₆H₅

Cbz
carbobenzyloxy, —C(═O)OCH₂C₆H₅

DMSO
dimethylsulfoxide

MeOH
methanol

EtOAc
ethyl acetate

Example: Evaluation of Candidate Transaminases

Candidate transaminases were evaluated using the reaction conditions described in Method A above (see Table 6). These experiments were carried out using PRM-102 (powder form) as the co-enzyme system and D-alanine or L-alanine as the amino donor molecule. In all but two of the runs, a water miscible co-solvent (methanol or trifluoroethanol (CF₃CH₂OH)) was employed. As shown in Table 6, % conversions of 5% and 15% were observed when the transamination was conducted in the presence of omega amine transaminase enzyme ATA-113, and % conversions of 2% and 3% were observed when the transamination was conducted in the presence of omega amine transaminase enzyme ATA-117. Omega amine transaminase enzymes ATA-117, known generally to be an (R)-selective transaminase, produced the compound (S)-(II-a) rather than compound (R)-(II-a). ATA-113, known generally to be an (S)-selective transaminase, produced the compound (S)-(II-a). The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Example: Evaluation of FDH/LADH/NAD Coenzyme Mixtures

Candidate mixtures of the co-enzymes FDH, LADH and NAD were evaluated using the reaction conditions described in Method B above (see Table 7). These experiments were carried out using ATA-117 and ATA-113 as the amine transferase enzyme; D-alanine as the amino donor molecule; and DMSO, methanol or trifluoroethanol as the co-solvent. As shown in Table 7, % conversions of from 1% to 37% were observed using this co-enzyme system. Further, transamination was achieved using either ATA-117 or ATA-113 as the transaminase enzyme. The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Example: Comparison of Omega Transaminase from Vibrio fluvialis with ATA-117 and ATA-113

The activity of the omega transaminase from Vibrio fluvialis was compared with the activities of ATA-117 and ATA-113 using the reaction conditions described in Method C above (see Table 8). These experiments were carried out using PRM-102 as the co-enzyme system and one of the following amino donor molecule: D-alanine, L-alanine, (S)-methyl benzylamine and (R)-methyl benzylamine. When ATA-117 or ATA-113 was employed as the transaminase enzyme, compound (S)-(II-a) was produced. As indicated in Table 8, this product stereochemistry (S) was obtained with amino donor molecules D-alanine, L-alanine, and (S)-methyl benzylamine. In contrast, when the omega amine transaminase from Vibrio fluvialis was employed as the amine transaminase enzyme, compound (R)-(II-a) was produced. As indicated in Table 8, this product stereochemistry was obtained when either (R) or (S)-methyl benzylamine was used as the amino donor molecule. The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Example: Evaluation of Candidate Amino Donor Molecules

Candidate amino donor molecules were evaluated using the reaction conditions described in Method D above (see Table 9). These experiments were carried out using the omega transaminase from Vibrio fluvialis; a 20 mM phosphate buffer (pH=7.0); and methanol as the co-solvent. L-alanine, D-alanine, (R)-methylbenzylamine, (S)-methylbenzylamine, 2-aminoindane, (R)-1-aminoindane, (R)-2-amino-1-propanol, (S)-2-amino-1-propanol, (1R,2S)-cis-1-amino-2-indanol, (1R,2R)-trans-1-amino-2-indanol, 1-(R)-amino-6-hydroxyindanamine and isopropylamine were tested. As indicated in Table 9, only compound (R)-(II-a) was observed. L-alanine as amino donor molecule provided a % conversion of 16.1% over a period of 7 days. The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Example: Evaluation of Candidate Reaction pH and Buffer Strengths

Candidate reaction pH and buffer strengths were evaluated using the reaction conditions described in Method E above (see Table 10). These experiments were carried out using buffers with different pH's and molarities. As shown in Table 10, a 20 mM phosphate buffer (maintaining a pH=8.0) was found to provide a % conversion of 14.9%. Increasing the molarity of the buffer (100 mM) was found to cause precipitation of the starting material (I-a) and reduce conversion to the product (R)-(II-a). The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Table 11 shows the results for transamination reactions conducted at pH=7.5. These reactions were monitored for any change in the pH, and any change in the pH of the reaction mixture was adjusted using 0.1 N sodium hydroxide solution (Method F). However, it was also found that the conversion was dependent on the age of the enzyme. A fresh bottle of enzyme was found to increase % conversion up to 31% using L-alanine over a period of 7 days and 2 units/mg of the substrate compound (I-a). When the reaction mixture was charged with an additional unit of fresh enzyme at the end of day 6, the conversion improved to 48.7%. The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Example: Evaluation of Candidate Additives

Candidate additives were evaluated using the reaction conditions described in Method G above (see Table 12). These experiments were carried out using additives, such as resins, cyclodextrins and sulfites. Resins capable of adsorbing the starting material compound (I-a) as well as the product compound (II-a) were screened. In addition, β- and γ-cyclodextrins that are known to solubilize organic compounds were also tested (% conversions of 14.0% and 11.4% were observed for β- and γ-cyclodextrin, respectively). The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Example: Evaluation of Candidate Co-Colvents

Candidate co-colvents were evaluated using the reaction conditions described in Method H above (see Table 13). For monophasic systems, it was found that using methanol as the co-solvent provided the highest % conversion of those tested. For biphasic systems, it was found that using ethyl acetate as the co-solvent provided the highest % conversion of those tested. The descriptor “n/a” indicates that the transamination product (II-a) was not detected by HPLC in the reaction mixture.

Exemplary Sulfonylation of a Compound of Formula (II)

embedded image

Procedure described in Tremblay et al., “Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)” J. Med. Chem. (2009) 52:4400-4418, incorporated herein by reference.

A solution of amine (R¹=CBz) (5.10 g, 9.09 mmol, 1 equiv) in dichloromethane (60 mL) was treated with diisopropylethylamine (5.88 g, 45.5 mmol, 5.0 equiv), cooled to 0° C., and treated with methanesulfonyl chloride (2.08 g, 18.2 mmol, 2.0 equiv). The reaction mixture was stirred for 30 min and partitioned between saturated aqueous sodium bicarbonate and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated to dryness to provide a crude residue. The residue was purified using silica gel chromatography (10-30% EtOAc/hexanes) to provide the N-Cbz sulfonylated product. A suspension of the isolated product and 10% palladium on carbon (1.0 g) in 2-propanol (50 mL) was placed under hydrogen atmosphere and stirred for 4 h at room temperature. The reaction mixture was then filtered on Celite and the filtrate concentrated to dryness. The residue was then purified using silica gel chromatography (0-5% DCM/MeOH) to give IPI-926 (4.06 g, 8.05 mmol, 95% for two steps). NMR δH (400 MHz, CDCl3) 6.90 (br s, 1H), 3.31 (dt, J=10.6, 3.8 Hz, 1H), 3.20 (br s, 1H), 3.10 (dd, J=13.7, 4.5 Hz, 1H), 2.91 (s, 3H), 2.62 (dd, J=9.9, 7.6 Hz, 1H), 2.33 (br d, J=14.5 Hz, 1H), 2.27-2.15 (m, 1H), 2.10 (dd, J=14.5, 6.9 Hz, 1H), 1.99-1.17 (m, 28H), 1.05 (q, J=11.6 Hz, 1H), 0.93 (d, J=7.4 Hz, 3H), 0.88 (d, J=6.6 Hz, 3H), 0.86 (s, 3H); NMR δC (100 MHz, CDCl3) 140.47, 124.53, 82.48, 76.97, 63.73, 54.08, 53.87, 50.12, 49.98, 47.19, 44.73, 42.27, 42.10, 40.24, 37.55, 37.44, 36.04, 34.44, 31.87, 31.33, 30.46, 29.79, 28.37, 27.94, 26.26, 24.19, 22.70, 18.92, 10.19; m/z=505.29 [M+H]+; HPLC 99.1 a/a % at 215 nm.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

1. A process for preparing a compound of formula (II):
2. The process of claim 1, wherein the co-factor is pyridoxal phosphate (PLP).
3. The process of claim 1, wherein the co-factor is a co-enzyme.
4. The process of claim 3, wherein the co-enzyme is selected from L-alanine dehydrogenase (LADH), lactate dehydrogenase (LDH), nicotinamide adenine dinucleotide phosphate (NADPH), nicotinamide adenine dinucleotide (NAD), formate dehydrogenase (FDH), and glucose dehydrogenase (GDH).
5. The process of claim 1, wherein the process further comprises adding a pyruvate reductase mix to the solution.
6. The process of claim 1, wherein the omega amine transaminase is selected from the group consisting of ATA-101, ATA-102, ATA-103, ATA-104, ATA-105, ATA-106, ATA-107, ATA-108, ATA-109, ATA-110, ATA-113, ATA-114, ATA-115, ATA-116, ATA-117, ATA-124, an omega amine transaminase from Chromobacterium violaceum, an omega amine transaminase from Alcaligenes denitrificans, an omega amine transaminase from Arthrobactercitreus, an omega amine transaminase from Klebsiella pneumoniae, an omega amine transaminase from Bacillus thuringiensis, an omega amine transaminase from Bacillus cereus, and an omega amine transaminase from Vibrio fluvialis.
7. The process of claim 1, wherein the amino donor molecule is selected from pyridoxamine, methylbenzylamine, 2-aminobutane, propyl amine, isopropyl amine, 1,1,1-trifluoropropan-2-amine, 1,1,1,3,3,3-hexafluoropropan-2-amine, benzyl amine, 2-amino-1-butanol, 1-amino-1-phenylethane, 1-amino-1-(2-methoxy-5-fluorophenyl)ethane, 1-amino-1-phenylpropane, 1-amino-1-(4hydroxyphenyl)propane, 1-amino-1-(4-bromophenyl)propane, 1-amino-1-(4-nitrophenyl)propane, 1-phenyl-2-aminopropane, 1-(3-trifluoromethylphenyl)-2-aminopropane, 2-aminopropanol, 1-amino-1-phenylbutane, 1-phenyl-2-aminobutane, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminobutane, 1-phenyl-3-aminobutane, 1-(4-hydroxyphenyl)-3-aminobutane, 1-amino-1-(2-naphthyl)ethane, cis-2-methylcyclopentanamine, trans-2-methylcyclopentanamine, cis-3-methylcyclopentanamine, trans-3-methylcyclopentanamine, cis-2-ethylcyclopentanamine, trans-2-ethylcyclopentanamine, cis-3-ethylcyclopentanamine, trans-3-ethylcyclopentanamine, cis-2-methylcyclohexanamine, trans-2-methylcyclohexanamine, cis-3-methylcyclohexanamine, trans-3-methylcyclohexanamine, cis-2-ethylcyclohexanamine, trans-2-ethylcyclohexanamine, cis-3-ethylcyclohexanamine, trans-3-ethylcyclohexanamine, 1-aminotetralin, 2-aminotetralin, 2-amino-5-methoxytetralin, 1-aminoindane, 2-aminoindane, 2-amino-1-propanol, cis-1-amino-2-indanol, trans-1-amino-2-indanol, 1-amino-6-hydroxyindanamine, taurine, and salts thereof.
8. The process of claim 1, wherein the amino donor molecule is selected from glycine, alanine, aspartic acid, phenylalanine, 2-aminopentanedioic acid, 3-aminobutyrate, γ-aminobutyrate, β-alanine, asparagine, cysteine, glutamic acid, glutamine, proline, selenocysteine, serine, tyrosine, arginine, histidine, ornithine, isoleucine, leucine, lysine, methionine, threonine, tryptophan, valine, and polypeptides thereof and/or salts thereof.
9. The process of claim 1, wherein the amino donor molecule is a chiral amino donor molecule.
10. The process of claim 1, wherein the solution is a buffered solution.
11. The process of claim 1, wherein the pH of the solution is between about 5 and about 9.
12. The process of claim 1, wherein R1 is H, aralkyl or —CO2R16.
13. The process of claim 1, wherein R2 and R3 taken together form a double bond or form a group:
14. The process of claim 1, wherein X is a bond or is the group —C(R19)2—.
15. The process of claim 1, wherein R4 is H.
16. The process of claim 1, wherein each of R5 and R6 is independently H, or R5 and R6 taken together with the carbon to which they are bonded form C═O.
17. The process of claim 1, wherein R7 and R8 are each H.
18. The process of claim 1, wherein R9 and R10 are each H.
19. The process of claim 1, wherein R11 is a H.
20. The process of claim 1, wherein R12 and R13 are each H.
21. The process according to claim 1, wherein R9 is H and R10 and R11 taken together form a double bond.
22. The process of claim 1, wherein R13 is H, and R11 and R12 taken together form a double bond.
23. The process of claim 1, wherein each of R9, R10, R11, R12, and R13 is H.
24. The process of claim 1, wherein R14 and R15 are each H.
25. The process of claim 1, wherein the compound of formula (I) or a salt thereof and a compound of formula (II) or a salt thereof are selected from a pair of compounds:
26. The process of claim 1, wherein the compound of formula (I) is a compound of formula (I-a):
27. The process of claim 1, further comprising contacting a compound of formula (II) or a salt thereof with a sulfonylating agent to provide a compound of formula (III):
28. The process of claim 27, wherein the sulfonylating agent is selected from benzenesulfonyl chloride, benzenesulfonyl anhydride, p-toluenesulfonyl chloride, p-toluenesulfonyl anhydride, methanesulfonyl chloride, and methanesulfonyl anhydride.
29. The process of claim 27, wherein the sulfonylating agent is methanesulfonyl chloride or methanesulfonyl anhydride, and R23 is —CH3.
30. The process of claim 1, wherein the process preferentially generates a compound of formula II or a salt thereof wherein the newly-formed amino group has R-stereochemistry.

Parent Case Info

This application is a continuation of U.S. application Ser. No. 14/257,658, filed Apr. 21, 2014, now abandoned which is a continuation of U.S. application Ser. No. 13/175,053, filed Jul. 1, 2011, now U.S. Pat. No. 8,703,448, which is a continuation of International Application No. PCT/US2010/044597, filed Aug. 5, 2010, which claims the benefit of U.S. Provisional Application No. 61/231,439, filed on Aug. 5, 2009, each of which is incorporated herein by reference in its entirety.

US Referenced Citations (150)

Number	Name	Date	Kind
4843071	Hohenwarter	Jun 1989	A
4968787	Inada et al.	Nov 1990	A
5086047	Gourvest et al.	Feb 1992	A
5169780	Stirling et al.	Dec 1992	A
5378475	Smith et al.	Jan 1995	A
5767161	Stroppolo et al.	Jun 1998	A
6177407	Rodgers et al.	Jan 2001	B1
6184381	Ikariya et al.	Feb 2001	B1
6238876	Altaba	May 2001	B1
6291516	Dudek et al.	Sep 2001	B1
6372931	Blacker et al.	Apr 2002	B1
6432970	Beachy et al.	Aug 2002	B2
6509467	Blacker et al.	Jan 2003	B1
6545188	Blacker et al.	Apr 2003	B2
6552016	Baxter et al.	Apr 2003	B1
6613798	Porter et al.	Sep 2003	B1
6686388	Dudek et al.	Feb 2004	B2
6867216	Beachy et al.	Mar 2005	B1
6887820	Ikariya et al.	May 2005	B1
6909003	Storz	Jun 2005	B2
7098196	Beachy et al.	Aug 2006	B1
7112690	Chi et al.	Sep 2006	B2
7230004	Adams et al.	Jun 2007	B2
7250526	Blacker et al.	Jul 2007	B2
7291626	Beachy et al.	Nov 2007	B1
7407967	Adams et al.	Aug 2008	B2
7476661	Beachy et al.	Jan 2009	B2
7541183	Rudnicki et al.	Jun 2009	B2
7605167	Tas et al.	Oct 2009	B2
7629352	Tas et al.	Dec 2009	B2
7648994	Castro et al.	Jan 2010	B2
7655674	Beachy et al.	Feb 2010	B2
7812164	Austad et al.	Oct 2010	B2
7867492	Beachy et al.	Jan 2011	B2
7875628	Adams et al.	Jan 2011	B2
7893078	Tas et al.	Feb 2011	B2
7964590	Castro et al.	Jun 2011	B2
7994191	Castro et al.	Aug 2011	B2
8017648	Castro et al.	Sep 2011	B2
8227509	Castro et al.	Jul 2012	B2
8236956	Adams et al.	Aug 2012	B2
8293760	Castro et al.	Oct 2012	B2
8426436	Castro et al.	Apr 2013	B2
8431566	Castro et al.	Apr 2013	B2
8669365	Austad et al.	Mar 2014	B2
8703448	Austad et al.	Apr 2014	B2
8716479	Austad et al.	May 2014	B2
8785635	Austad et al.	Jul 2014	B2
8895576	Castro et al.	Nov 2014	B2
9145422	Castro et al.	Sep 2015	B2
9238672	Austad et al.	Jan 2016	B2
9376447	Genov et al.	Jun 2016	B2
9394313	Genov et al.	Jul 2016	B2
9492435	Austad et al.	Nov 2016	B2
20020006931	Beachy et al.	Jan 2002	A1
20020087258	Johnson	Jul 2002	A1
20020193347	Bulliard et al.	Dec 2002	A1
20030114393	Liscovitch et al.	Jun 2003	A1
20030162870	Kimura et al.	Aug 2003	A1
20030175355	Tobyn et al.	Sep 2003	A1
20030220314	Shackleton et al.	Nov 2003	A1
20040023949	Baxter et al.	Feb 2004	A1
20040072913	Tas et al.	Apr 2004	A1
20040072914	Tas et al.	Apr 2004	A1
20040073404	Brooks et al.	Apr 2004	A1
20040110663	Dudek et al.	Jun 2004	A1
20040126359	Lamb et al.	Jul 2004	A1
20040127474	Dudek et al.	Jul 2004	A1
20040247643	Martinod et al.	Dec 2004	A1
20050049218	Gilbertson	Mar 2005	A1
20050112707	Altaba et al.	May 2005	A1
20050203061	Yamashita et al.	Sep 2005	A1
20060020020	Dudek et al.	Jan 2006	A1
20060074030	Adams et al.	Apr 2006	A1
20060094660	Thomson	May 2006	A1
20060128639	Beachy	Jun 2006	A1
20060142245	Beachy et al.	Jun 2006	A1
20060252073	Yilmaz et al.	Nov 2006	A1
20070003550	Antonia et al.	Jan 2007	A1
20070009530	Altaba et al.	Jan 2007	A1
20070021493	Guicherit et al.	Jan 2007	A1
20070036800	Bergstein	Feb 2007	A1
20070060546	Ruat et al.	Mar 2007	A1
20070179091	De Sauvage et al.	Aug 2007	A1
20070191410	Adams et al.	Aug 2007	A1
20070219250	Singh et al.	Sep 2007	A1
20070231828	Beachy et al.	Oct 2007	A1
20070281040	Weichselbaum et al.	Dec 2007	A1
20080019961	Wicha et al.	Jan 2008	A1
20080057071	Watkins et al.	Mar 2008	A1
20080058298	Beachy et al.	Mar 2008	A1
20080089915	Tas et al.	Apr 2008	A1
20080095761	Beachy et al.	Apr 2008	A1
20080107749	Maitra et al.	May 2008	A1
20080118493	Beachy et al.	May 2008	A1
20080138379	Jennings-Spring	Jun 2008	A1
20080182859	Brunton et al.	Jul 2008	A1
20080255059	Beachy et al.	Oct 2008	A1
20080262051	Balkovec et al.	Oct 2008	A1
20080269182	Pluda et al.	Oct 2008	A1
20080269272	Adams et al.	Oct 2008	A1
20080287420	Castro et al.	Nov 2008	A1
20080293754	Austad et al.	Nov 2008	A1
20080293755	Castro et al.	Nov 2008	A1
20090012109	Austad et al.	Jan 2009	A1
20090041680	Tamarkin et al.	Feb 2009	A1
20090181997	Grayzel et al.	Jul 2009	A1
20090208579	Ueki et al.	Aug 2009	A1
20090216022	Austad et al.	Aug 2009	A1
20090246841	Jamieson	Oct 2009	A1
20090263317	Chen et al.	Oct 2009	A1
20090286822	Tas et al.	Nov 2009	A1
20090305338	Ritala-Nurmi et al.	Dec 2009	A1
20100003728	Jayatilake et al.	Jan 2010	A1
20100093625	Tarasova et al.	Apr 2010	A1
20100099116	Faia et al.	Apr 2010	A1
20100144775	Castro et al.	Jun 2010	A1
20100210515	Nash et al.	Aug 2010	A1
20100222287	McGovern et al.	Sep 2010	A1
20100273818	Beachy et al.	Oct 2010	A1
20100286114	Thomas et al.	Nov 2010	A1
20100286180	Castro et al.	Nov 2010	A1
20100297118	MacDougall et al.	Nov 2010	A1
20110009442	Austad et al.	Jan 2011	A1
20110034498	McGovern et al.	Feb 2011	A1
20110104254	Tas et al.	May 2011	A1
20110135739	Carter et al.	Jun 2011	A1
20110166353	Adams et al.	Jul 2011	A1
20110183948	Levine et al.	Jul 2011	A1
20110230509	Castro et al.	Sep 2011	A1
20120010229	MacDougall et al.	Jan 2012	A1
20120010230	MacDougall et al.	Jan 2012	A1
20120015934	Castro et al.	Jan 2012	A1
20120065218	Castro et al.	Mar 2012	A1
20120065399	Genov et al.	Mar 2012	A1
20120065400	Genov et al.	Mar 2012	A1
20120077834	Castro et al.	Mar 2012	A1
20120083484	Castro et al.	Apr 2012	A1
20120083607	Austad et al.	Apr 2012	A1
20130108582	Castro et al.	May 2013	A1
20130108583	Castro et al.	May 2013	A1
20130143831	Embil et al.	Jun 2013	A1
20140107142	Castro et al.	Apr 2014	A1
20140371253	Austad et al.	Dec 2014	A1
20140371456	Austad et al.	Dec 2014	A1
20160168193	Jayatilake et al.	Jun 2016	A1
20160177354	Austad et al.	Jun 2016	A1
20160354368	Brown et al.	Dec 2016	A1
20170022212	Austad et al.	Jan 2017	A1
20170029433	Genov et al.	Feb 2017	A1

Foreign Referenced Citations (70)

Number	Date	Country
0255331	Feb 1988	EP
0388188	Sep 1990	EP
0434570	Jun 1991	EP
2225254	Sep 2010	EP
2443926	Apr 2012	EP
2010-0514796	May 2010	JP
WO 1994020520	Sep 1994	WO
WO 1995018856	Jul 1995	WO
WO 1996017924	Jun 1996	WO
WO 1997013518	Apr 1997	WO
WO 1999049835	Oct 1999	WO
WO 2000018708	Apr 2000	WO
WO 2000041545	Jul 2000	WO
WO 2001009077	Feb 2001	WO
WO 2001019800	Mar 2001	WO
WO 2001026644	Apr 2001	WO
WO 2001027135	Apr 2001	WO
WO 2001049279	Jul 2001	WO
WO 2001074344	Oct 2001	WO
WO 2001090077	Nov 2001	WO
WO 2002030462	Apr 2002	WO
WO 2002078703	Oct 2002	WO
WO 2002078704	Oct 2002	WO
WO 2003011219	Feb 2003	WO
WO 2003088964	Oct 2003	WO
WO 2003088970	Oct 2003	WO
WO 2004020599	Mar 2004	WO
WO 2004058976	Jul 2004	WO
WO 2005013800	Feb 2005	WO
WO 2005032343	Apr 2005	WO
WO 2005033288	Apr 2005	WO
WO 2005042700	May 2005	WO
WO 2006026430	Mar 2006	WO
WO 2006028958	Mar 2006	WO
WO 2006050351	May 2006	WO
WO 2006078283	Jul 2006	WO
WO 2007053596	May 2007	WO
WO 2007054623	May 2007	WO
WO 2007059157	May 2007	WO
WO 2007093372	Aug 2007	WO
WO 2007120827	Oct 2007	WO
WO 2007123511	Nov 2007	WO
WO 2007131201	Nov 2007	WO
WO 2008011071	Jan 2008	WO
WO 2008037732	Apr 2008	WO
WO 2008063165	May 2008	WO
WO 2008070357	Jun 2008	WO
WO 2008083248	Jul 2008	WO
WO 2008083252	Jul 2008	WO
WO 2008089123	Jul 2008	WO
WO 2008109184	Sep 2008	WO
WO 2008109829	Sep 2008	WO
WO 2008110611	Sep 2008	WO
WO 2008112913	Sep 2008	WO
WO 2008131354	Oct 2008	WO
WO 2009086416	Jul 2009	WO
WO 2009086451	Jul 2009	WO
WO 2009099625	Aug 2009	WO
WO 2009126840	Oct 2009	WO
WO 2010000070	Jan 2010	WO
WO 2010002970	Jan 2010	WO
WO 2010085654	Jul 2010	WO
WO 2011017551	Feb 2011	WO
WO 2011041075	Apr 2011	WO
WO 2011057222	May 2011	WO
WO 2011063309	May 2011	WO
WO 2012006584	Jan 2012	WO
WO 2012006589	Jan 2012	WO
WO 2012037217	Mar 2012	WO
WO 2013049332	Apr 2013	WO

Non-Patent Literature Citations (291)

Entry
Taylor et al. Tibtech (1998) 16: 412-418.
Cancer Cluster Salzburg, “CCS researchers identify imiquimod as novel Hedgehog pathway inhibitor in skin cancer”, Apr. 29, 2014, retrieved form the internet: URL: http://www.cancercluster-salzberg.at/#!CCS-researchers-identify-imiquimod-as-novel-Hedgehog-pathway-inhibitor-in-skin-cancer/axycm/5687b39c0cf23a10fe3c91fc, accessed on Sep. 28, 2016.
Deng et al., “External preparation useful for preparing drug for treating infectious disease caused by fungi, comprises nanosized itraconazole and matrix”, Database WPI, Thomson Scientific, London, GB, AN: 2011-H84807, PN: CN102085176, 4 pgs. (2011) Abstract.
Jiang et al., “Solution type spray of animycotic medicine for external application and its preparation method”, Database WPI, Thomson Scientific, London, GB, AN: 2003-258153, PN: CN1380060, 4 pgs (2002) Abstract.
Park et al., “Composition useful for treating skin fungal infections, comprises itraconazole, phenol and phenolic alcohol”, Database WPI, Thomson Scientific, London, GB, AN: 2010-F87592, PN: KR20100051293, 4 pgs. (2010) Abstract.
Tang et al., “Antitumor activity of extracts and compounds from the rhizomes of Veratrum dahuricum”, Phytother. Res., vol. 22, No. 8, pp. 1093-1096 (2008).
Hashimoto, “Simmons-Smith reaction without hydroxyl groups”, Chemical, vol. 61, No. 1, pp. 63-64 (2006) Japanese language with English translation.
Simmons and Smith, “A new synthesis of cyclopropanes from olefins”, J. Am. Chem. Soc., vol. 80, No. 19, pp. 5323-5324 (1958).
Tschesche et al., “Concerning the biosynthesis of steroid derivatives in the plant kingdom, 3rd mess.1: Spirostanol-biogenesis from cholesterol-glucoside”, Z. Naturforsch, vol. 21b pp. 494-495 (1966) German language with English translation.
Aboulkassim et al., “Alteration of the PATCHED locus in superficial bladder cancer”, Oncogene, vol. 22, No. 19, pp. 2967-2971 (2003).
Ahlford, “Asymmetric transfer hydrogenation of ketones, catalyst development and mechanistic investigation”, Department of Organic Chemistry, Stockholm University, US-AB Stockholm, pp. 1-49 (2011).
Ailles and Siu, “Targeting the hedgehog pathway in cancer: can the spines be smoothened?”, Clin. Cancer Res.; vol. 17, No. 8, pp. 2071-2073 (2011).
Alexandre et al., “Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the Cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins”, Genes Dev., vol. 10, pp. 2003-2013 (1996).
Alonso et al., “Ru(arene)(amino alcohol)-catalyzed transfer hydrogenation of ketones: mechanism and origin of enantioselectivity”, J. Am. Chem. Soc., vol. 121, pp. 9580-9588 (1999).
Athar et al., “Hedgehog signaling in skin development and cancer”, Exp. Dermatol., vol. 15, No. 9, pp. 667-677 (2006).
Bailey et al., “Sonic hedgehog promotes desmoplasia in pancreatic cancer”, Clin. Cancer Res., vol. 14, No. 19, pp. 5995-6004 (2008).
Bailey et al., “Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer”, Oncogene, vol. 28, No. 40, pp. 3513-3525 (2009).
Bale and Yu, “The hedgehog pathway and basal cell carcinomas”, Human Molecular Genetics, vol. 10, No. 7, pp. 757-762 (2001).
Banerjee et al., “Recruitment of the sonic hedgehog signalling cascade in electroconvulsive seizure-mediated regulation of adult rat hippocampal neurogenesis”, Eur. J. Neurosci., vol. 22, No. 7, pp. 1570-1580 (2005).
Bar et al., “Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma”, Stem Cells, vol. 25, No. 10, pp. 2524-2533 (2007).
Barken et al., “Noscapine inhibits human prostate cancer progression and metastasis in a mouse model”, Anticancer Res., vol. 28, No. 6A, pp. 3701-3704 (2008).
Belloni et al., “Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly”, Nature Genetics, vol. 14, pp. 353-356 (1996).
Berge et al., “Pharmaceutical salts”, J. Pharm. Sci., 66, No. 1, pp. 1-19 (1977).
Berger et al., “Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovacularization”, Blood, vol. 105, No. 3, pp. 1094-1101 (2005).
Berman et al., “Medulloblastoma growth inhibition by hedgehog pathway blockade”, Science, vol. 297, pp. 1559-1561 (2002).
Berman et al., “Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours”, Nature, vol. 425, pp. 846-851 (2003).
Bhat et al., “Synthesis and biological evaluation of novel steroidal pyrazoles as substrates for bile acid transporters”, Bioorg. Med. Chem. Lett., vol. 15, pp. 85-87 (2005).
Bhattacharya et al., “Role of Hedgehog signaling in ovarian cancer”, Clin. Cancer Res., vol. 14, No. 23, pp. 7659-7666 (2008).
Biospace, Print News Article, “Infinity Pharmaceuticals, Inc. Announces Hedgehog Pathway Inhibitor Agreement with AstraZeneca PLC (AZ)”, Cambridge, Mass., Nov. 12, 2007, (Prime Newswire), 2 pages, Retrieved from the internet: http://www.biospace.com/news—story.aspx?NewsEntityID=77067.
Brown and Keeler, “Structure-activity relation of steroid teratogens, 1. Jervine ring system”, J. Agric. Food Chem., vol. 26, No. 3, pp. 561-563 (1978).
Brown and Keeler, “Structure-activity relation of steroid teratogens, 2. N-substituted jervines”, J. Agric. Food Chem., vol. 26, No. 3, pp. 564-566 (1978).
Browne et al., “Isolation of teratogenic alkaloids by reversed-phase high-performance liquid chromatography” Journal of Chromatography Biomedical Applications, vol. 336, pp. 211-220 (1984).
Business Wire, “Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer”, Infinity Pharmaceuticals, 3 pages, Jan. 27, 2012, Retrieved from the internet: http://www.businesswire.com/news/home/20120127005146/en/Infinity-Reports-Update-Phase-2-Study-Saridegib#.U3Us—IdV8E.
Campbell et al., “Direct Targeting of the Hedgehog pathway in primary chondrosarcoma xenografts with smoothened Inhibitor IPI-926”, Infinity Pharmaceuticals, Inc., Presentation Poster, Abstract #LB380, 1 page (2011).
Carter et al., “Formulation for IPI-926 drug product, a novel oral Hedgehog pathway inhibitor in clinical development”, Infinity Pharmaceuticals, Inc., Presentation Poster, Abstract #M1169, with Presentation Abstract, 2 pages (2009).
Caserta et al., “p63 overexpression induces the expression of sonic hedgehog”, Mol. Cancer Res., vol. 4, No. 10, pp. 759-768 (2006).
Chaumeil, “Micronization: A method of improving the bioavailability of poorly soluble drugs”, Methods Find. Exp. Clin. Pharmacol., vol. 20, No. 3, pp. 211-215 (1998).
Chen et al., “Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened”, Genes Dev., vol. 16, No. 21, pp. 2743-2748 (2002).
Chen et al., “Small molecule modulation of Smoothened activity”, PNAS, vol. 99, No. 22, pp. 14071-14076 (2002).
Chen et al., “Targeting the hedgehog pathway to mitigate treatment resistance”, Cell Cycle, vol. 6, Issue. 15, pp. 1826-1830 (2007).
Chen et al., “Sonic hedgehog dependent phosphorylation by CK1α and GRK2 is required for ciliary accumulation and activation of smoothened”, PloS Biology, vol. 9, Issue. 6, No. e1001083, 16 pages (2011).
Christiansen et al., “Antiandrogenic steroidal sulfonylpyrazoles”, J. Med. Chem., vol. 33, pp. 2094-2100 (1990).
Chung et al., “New targets for therapy in prostate cancer; modulation of stromal-epithelial interactions”, Urology, vol. 62, Suppl. 5A, pp. 44-54 (2003).
Clement et al., “Hedgehog-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal and tumorigenicity”, Curr. Biol., vol. 17, No. 2, pp. 165-172 (2007).
Clinton et al., “Steroidal heterocycles, VI. Formulation of A/B-cis 3-Ketosteroids. Preparation of 5β-Steroidal[3,2-c]pyrazoles”, J. Org. Chem., vol. 27, pp. 2800-2807 (1962).
COMTEX, “Infinity announces hedgehog pathway inhibitor agreement with Astra-Zeneca”, Infinity Pharmaceuticals, PrimeWireNewswire via COMTEX News Network, 2 pages, Nov. 12, 2007, Retrieved from the internet: http://files.shareholder.com/downloads/INFI/0x0x144355/71ecb752-43b2-4a26-9867-8feea13ee93d/INFI—News—2007—11—12—General.pdf.
Cong et al., “Steroidal alkaloids from the roots and rhizomes of Veratrum nigrum L”, Helvetica Chimica Acta, vol. 90, Issue 5, pp. 1038-1042 (2007).
Cooper et al., “Teratogen-mediated inhibition of target tissue response to Shh signaling”, Science, vol. 280, pp. 1603-1607 (1998).
Corbit et al., “Vertebrate smoothened functions at the primary cilium”, Nature, vol. 437 No. 7061, pp. 1018-1021 (2005).
Cutcliffe et al., “Clear cell sarcoma of the kidney: Up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways”, Clin. Cancer Res., vol. 11, No. 22, pp. 7986-7994 (2005).
Dakhova et al., “Global gene expression analysis of reactive stroma in prostate cancer”, Clin. Cancer Res., vol. 15, No. 12, pp. 3979-3989 (2009).
Dersnah and Baird, “Chiral η6-C6H6 ruthenium complexes”, J. Org. Chem., vol. 127, C55-C58 (1977).
Dierks et al., “Essential role of stromally induced hedgehog signaling in B-cell malignancies”, Nat. Med., vol. 13, No. 8, pp. 944-951 (2007) Pre Publication Article, DOI:10.1038/nm1614 pp. 1-8 (2007).
Dierks et al., “Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation”, Cancer Cell, vol. 14, No. 3, pp. 238-249 (2008).
Di Magliano and Hebrok, “Hedgehog signalling in cancer formation and maintenance”, Nat. Rev., vol. 3, No. 12, pp. 903-911 (2003).
Djerassi and Gutzwiller, “Selective reduction of steroids by homogeneous catalytic hydrogenation”, J. Am. Chem. Soc., vol. 88, No. 19, pp. 4537-4538 (1966).
Dormeyer et al., “Plasma membrance proteomics of human embryonic stem cells and human embryonal carcinoma cells”, J. Proteome Res., vol. 7, No. 7, pp. 2936-2951 (2008).
Dörwald, “Side reactions in organic synthesis, A guide to successful synthesis design”, Wiley-VCH, Verlag GmbH & Co. KGaA, Weinheim, ISBN:3-527-31021-5, p. IX of Preface and pp. 8-13 (2005).
Ehtesham et al., “Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells”, Oncogene, vol. 26, No. 39, pp. 5752-5761 (2007).
Engelman and Settleman, “Acquired resistance to tyrosine kinase inhibitors during cancer therapy”, Curr, Opin. Genet. Dev., vol. 18, No. 1, pp. 73-79 (2008).
Everaere et al., “Ruthenium (II)-catalyzed asymmetric transfer hydrogenation of carbonyl compounds with 2-propanol and ephedrine-type ligands”, Adv. Synth. Catal., vol. 345, No. 1&2, pp. 67-77 (2003).
Fahrenholtz et al., “Cycloprop[16α, 17α] androstanes”, J. Med. Chem., vol. 15, No. 10, pp. 1056-1060 (1972).
Faia et al., “Depilation induced anagen as a model to study hedgehog pathway antagonist IPI-926: Implications for biomarker development”, AACR Meeting Abstracts Online, Abstract #2827, with Infinity Pharmaceuticals Poster, 3 pages (2008).
Fan et al., “Hedgehog singaling promotes prostate xenograft tumor growth”, Endocrinology, vol. 145, No. 8, pp. 3961-3970 (2004).
Feldmann et al., “Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers”, Cancer Res., vol. 67, No. 5, pp. 2187-2196 (2007).
Feldmann et al., “An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer”, Mol. Cancer Ther., vol. 7, No. 9, pp. 2725-2735 (2008).
Geng et al., “Hedgehog signaling in the murine melanoma microenvironment”, Angiogenesis, vol. 10, No. 4, pp. 259-267, DOI: 10.1007/s10456-007-9078-9 (2007).
Genov and Ager, “Asymmetric hydrogenation of ketones catalyzed by RuII-bicp complexes”, Angew. Chem. Int. Ed. Engl., vol. 43, No. 21, pp. 2816-2819 (2004).
Giannis et al., “Synthesis of cyclopamine using a biomimetic and diastereoselective approach”, Angew. Chem. Int. Ed., vol. 48, pp. 1-5 (2009).
Goldberg et al., “Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449”, Arch Dematol., vol. 147, No. 7, pp. 839-841 (2011).
Green, “A new approach to the formal classification of covalent compounds of the elements”, Journal of Organometallic Chemistry, vol. 500, Issue 1-2, pp. 127-148 (1995).
Grogan et al., “Synthesis and structure activity relationship of D-homo cyclopamine analogs: A-ring fused heterocyclic analogs”, MEDI 97, 237th ACS National Meeting, Infinity Pharmaceuticals, Inc., Presentation Poster, with Presentation Abstract, 2 pgs. (2009).
Growdon et al., “Hedgehog pathway inhibitor cyclopamine suppresses Gli1 expression and inhibits serous ovarian cancer xenograft growth”, 40th Annual Meeting on Women's Cancer, Feb. 5-8, 2009, Presentation Slides, 16 pages (2009).
“Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics”, US Dept. of Health Services, FDA, CDER and CBER, Section III, p. 4-9 (2007).
Guijarro et al., “Achiral β-amino alcohols as efficient ligands for the ruthenium-catalysed asymmetric transfer hydrogenation of sulfinylimines”, Tetrahedron Letters, vol. 52, Issue 7, pp. 789-791 (2011), pre-publication accepted manuscript, DOI:10.1016/j.tetlet.2010.12.031, 6 pgs. (2010).
Hanahan et al., “Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice”, J. Clin. Inv., vol. 105, No. 8, pp. 1045-1047 (2000).
Harrington et al., “Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model,” Br. J. Cancer, vol. 91, No. 2, pp. 366-373 (2004).
Harris et al., “Hedgehog signaling: Networking to nurture a premalignant tumor microenvironment”, Mol. Cancer Res., vol. 9, No. 9, pp. 1165-1174 (2011).
Hashiguchi et al., “Asymmetric transfer hydrogenation of aromatic ketones catalyzed by chiral ruthenium (II) complexes”, J. Am. Chem. Soc., vol. 117, No. 28, pp. 7562-7563 (1995).
Hawley's Condensed Chemical Dictionary, 15th edition, Lewis, ed., John Wiley & Sons, New York, pp. 38 and 100 (2007).
Heftmann, “Recent progress in the biochemistry of plant steroids other than steroids (saponins, glycoalkaloids, pregnana derivatives, cardiac glycosides, and sex hormones)”, Lipids, vol. 9, No. 8, pp. 626-639 (1974).
Hegde et al., “Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target”, Mol. Cancer Res., vol. 6, No. 12, pp. 1928-1936 (2008).
Heretsch et al., “Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives”, Angew. Chem. Int. Ed., vol. 49, pp. 2-12, DOI: 10.1002/anie.200906967 (2010).
Holton and Necoechea, “Steroids. CLXXV. Further steroidal anabolic agents”, J. Med. Chem., pp. 1352-1357 (1962).
Huangfu et al., “Hedgehog signalling in the mouse requires intraflagellar transport proteins”, Nature, vol. 426, No. 6962, pp. 83-87 (2003).
Ikariya et al., “Bifunctional transition metal-based molecular catalysts for asymmetric synthesis”, Org. Biomol. Chem., vol. 4, No. 3, pp. 393-406 (2006).
Incardona et al., “Cyclopamine inhibition of sonic hedgehog signal transduction is not mediated through effects on cholesterol transport”, Dev. Biol., vol. 224, No. 2, pp. 440-452 (2000).
International Search Report from International Patent Application No. PCT/US2005/030406, 2 pages, dated Apr. 4, 2006, application now published as International Patent Publication No. WO2006/026430 on Mar. 9, 2006.
International Search Report from International Patent Application No. PCT/US2006/010796, 9 pages, dated May 15, 2008.
International Search Report from International Patent Application No. PCT/US2007/088990, 2 pages, dated Aug. 1, 2008.
International Search Report from International Patent Application No. PCT/US2007/088995, 6 pages, dated Aug. 1, 2008.
International Search Report from International Patent Application No. PCT/US2008/003200, 3 pages, dated Aug. 11, 2008.
International Search Report from International Patent Application No. PCT/US2008/050970, 3 pages, dated Aug. 22, 2008.
International Search Report from International Patent Application No. PCT/US2008/056229, 4 pages, dated Aug. 11, 2008.
International Search Report from International Patent Application No. PCT/US2008/088222, 6 pages, dated Feb. 23, 2009.
International Search Report from International Patent Application No. PCT/US2008/088302, 1 pages, dated Mar. 25, 2009.
International Search Report from International Patent Application No. PCT/US2009/049372, 3 pages, dated Mar. 16, 2010.
International Search Report from International Patent Application No. PCT/US2010/021816, 3 pages, dated Jun. 2, 2010.
International Search Report from International Patent Application No. PCT/US2010/044597, 2 pages, dated Oct. 1, 2010.
International Search Report from International Patent Application No. PCT/US2010/055879, 12 pages, dated Jan. 24, 2011.
International Search Report from International Patent Application No. PCT/US2010/057534, 2 pages, dated Jan. 18, 2011.
International Search Report from International Patent Application No. PCT/US2011/043446, 5 pages, dated Oct. 16, 2012.
International Search Report from International Patent Application No. PCT/US2011/043453, 4 pages, dated Mar. 14, 2012.
International Search Report from International Patent Application No. PCT/US2011/051553, 2 pages, dated Feb. 2, 2012.
Iselin et al., “Structure of jervine, VI. The sulfuric acid-catalyzed acetolysis of N-acetyl-3-deoxy-3 alpha.-chlorotetrahydro jervine”, J. Am. Chem. Soc., vol. 76, pp. 5616-5620 (1954) Database Accession No. 1955:73589, XP-002672119, 4 pgs. (1954).
Iselin et al., “Jervine, IX. Miscellaneous new derivatives”, J. Am. Chem. Soc., vol. 78, No. 2, pp. 403-407 (1956) Database Accession No. 1956:69487, XP-002672116. 3 pgs. (1956).
Jacobs and Craig, “The veratrine alkaloids, XXII. On pseudojervine and veratrosine, a companion glycoside in veratrum viride”, J. Biol. Chem., vol. 155, 565-572 (1944).
Jacobs and Craig, “The veratrine alkaloids, XXV. The alkaloids of veratrum viride”, J. Biol. Chem., vol. 160, pp. 555-565 (1945).
Jacobs and Huebner, “Veratrine alkaloids, XXVII. Further studies with jervine”, J. Biol. Chem., vol. 170, pp. 635-652 (1947).
James et al., “Biomedical applications of poisonous plant research”, J. Agric. Food Chem., vol. 52, pp. 3211-3230 (2004).
Ji et al., “Protein kinase A, not EPAC, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells”, J. Biol. Chem., vol. 282, No. 52, pp. 37370-37377 (2007).
Kaneko et al., “Biosynthesis of C-nor-D-homo-steroidal alkaloids from acetate-I-14C, cholesterol-4-14C and cholesterol-26-14C in veratrum grandiflorum”, Phytochemistry, vol. 9, pp. 2489-2495 (1970).
Kaneko et al., “11-deoxojervine as a precursor for jervine biosynthesis in veratrum grandiflorum”, Phytochemistry, vol. 9, pp. 2497-2501 (1970).
Kaneko et al., “Conversion of solanidine to jervatrum alkaloids in veratrum grandiflorum”, Phytochemistry, vol. 11, pp. 3199-3202 (1972).
Kaneko et al., “Biosynthesis of rubijervine in veratrum grandiflorum” Phytochemistry, vol. 14, pp. 1295-1301 (1975).
Kaneko et al., “Origin of nitrogen in the biosynthesis of solanidine by veratrum grandiflorum”, Phytochemistry, vol. 15, pp. 1391-1393 (1976).
Kaneko et al., “Dormantinol, a possible precursor in solanidine biosynthesis from budding veratrum grandiflorum”, Phytochemistry, vol. 16, pp. 1247-1251 (1977).
Karhadker et al., “Hedgehog signalling in prostate regeneration, neoplasia and metastasis”, Nature, 431, pp. 707-712 (2004).
Kayed et al., “Distribution of indian hedgehog and its receptors patched and smoothened in human chronic pancreatitis”, J. Endocrinol., vol. 178, No. 3, pp. 467-478 (2003).
Kayed et al., “Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer”, Int. J. Cancer; vol. 110, No. 5, pp. 668-676 (2004).
Keeler and Binns, “Chemical compounds of veratrum californicum related to congenital ovine cyclopian malformations: extraction of active material”, Proc. Soc. Exptl. Biol. Med., vol. 116, pp. 123-127 (1964).
Keeler and Binns, “Teratogenic compounds of veratrum californicum (Durand), I. Preparation and characterization of fractions and alkaloids for biologic testing”, Canadian Journal of Biochemistry, vol. 44, No. 6, pp. 819-828 (1966).
Keeler and Binns, “Teratogenic compounds of veratrum californicum (Durand), II. Production of ovine fetal cyclopia by fractions and alkaloid preparations”, Can. J. Biochem., vol. 44, pp. 829-838 (1966).
Keeler, “Teratogenic compounds of veratrum californicum (Durand), IV. First isolation of veratramine and alkaloid Q and a reliable method for isolation of cyclopamine”, Phytochemistry, vol. 7, pp. 303-306 (1968).
Keeler, “Toxic and teratogenic alkaloids of western range plants”, J. Agr. Food Chem., vol. 17, No. 3, pp. 473-482 (1969).
Keeler, “Teratogenic Compounds of Veratrum Californicum (Durand) VII. The Structure of the glycosidic alkaloid cycloposine”, Steroids, vol. 13, No. 5, pp. 579-588 (1969).
Keeler and Binns, “Teratogenic compounds of veratrum californicum as a function of plant part, stage, and site of growth”, Phytochemistry, vol. 10, pp. 1765-1769 (1971).
Keeler, “Isolation of rubijervine from veratrum-californicum”, Phytochemistry, vol. 13, pp. 2336-2337 (1974).
Keeler and Baker, “Oral, osmotic minipump, and intramuscular administration to sheep of the veratrum alkaloid cyclopamine (42970)”, Cyclopamine Administration to Sheep, P.S.E.B.M., vol. 192, pp. 153-156 (1989).
Kenney et al., “Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors”, Development, vol. 131, No. 1, pp. 217-228 (2004).
Kerbal and Kamen, “The anti-angiogenic basis of metronomic chemotherapy”, Nature Rev., Cancer, vol. 4, pp. 423-436 (2004).
King, “Roughening up smoothened: chemical modulators of hedgehog signaling”, J. Biol., vol. 1, No. 8, pp. 8.1-8.4 (2002).
Kitajima et al., “Steroid alkaloids of fresh bulbs of fritillaria thunbergii miq. and of crude drug “BAI-MO” prepared therefrom”, Heterocycles, vol. 15, No. 2, pp. 791-796 (1981).
Koszelewski et al., “Formal asymmetric biocatalytic reductive amination”, Angew. Chem. Int. Ed., vol. 47, No. 48, pp. 9337-9340 (2008).
Koszelewski et al., “ω-transaminases for the synthesis of non-racemic α-chiral primary amines”, Trends Biotechnol., vol. 28, No. 6, pp. 324-332 (2010).
Kubo et al., “Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer”, Cancer Research, vol. 64, pp. 6071-6074 (2004).
Lacasse et al., “Iodomethylzinc phosphates: powerful reagents for the cyclopropanation of alkenes”, J. Am. Chem. Soc., vol. 127, No. 36, pp. 12440-12441 (2005).
Lee et al., “Development of an enzyme-linked immunosorbent assay for the veratrum plant teratogens: cyclopamine and jervine”, J. Agric. Food Chem., vol. 51, No. 3, pp. 582-586 (2003).
Leontjev et al., “Reduction of steroidal ketones with amine-boranes”, Russian Chemical Bulletin, vol. 53, No. 3, pp. 703-708 (2004).
Lescarbeau et al., “Synthesis and structure activity relationship of D-homo cyclopamine hedgehog antagonists: 7-membered A-ring lactam analogs”, MEDI 98, 237th ACS National Meeting, Infinity Pharmaceuticals, Inc., Poster, with Presentation Abstract, 2 pgs. (2009).
Lewis and Veltmaat, “Next stop, the twilight zone: hedgehog network regulation of mammary gland development”, J. Mamm. Gland Biol. Neopl., vol. 9, No. 2, pp. 165-181 (2004).
Li et al., “Chemistry, bioactivity and geographical diversity of steroidal alkaloids from the Liliaceae family”, Natural Product Reports, vol. 23, pp. 735-752 (2006).
Li et al., “Mesodermal deletion of transforming growth factor-β receptor II disrupts lung epithelial morphogenesis: cross-talk between TGF-β and sonic hedgehog pathways”, J. Biol. Chem., vol. 283, No. 52, pp. 36257-36264 (2008).
Lin et al., “Self-renewal of acute lymphocytic leukemia cells is limited by the hedgehog pathway inhibitors cyclopamine and IPI-926”, PLoS One, vol. 5, Issue 12, No. e15262, pp. 1-8 (2010).
Lindemann, “Stroma-initiated hedgehog signaling takes center stage in B-cell lymphoma”, Cancer Res., vol. 68, No. 4, pp. 961-964 (2008).
Lipinski et al., “Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse”, Toxicol. Sci. Advanced Access Publication, 28 pages, (2008).
Ma et al., “Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas”, Carcinogenesis, vol. 26, No. 10, pp. 1698-1705 (2005).
Ma et al., “Study of sonic hedgehog signaling pathway related molecules in gastric carcinoma”, World J. Gastroenterol., vol. 12, No. 25, pp. 3965-3969 (2006).
Ma et al., “Development of in vitro techniques for the important medicinal plant veratrum californicum”, Planta Medica, vol. 72, pp. 1142-1148 (2006).
Mandley et al., “The Hh inhibitor IPI-926 delays tumor re-growth of a non-small cell lung cancer xenograft model following treatment with an EGFR targeted tyrosine kinase inhibitor”, Infinity Pharmaceuticals, Inc., Presentation Poster, Abstract #5045, 1 page (2010).
Manna et al., “Metabolite identification of IPI-609, a novel and potent inhibitor of the hedgehog pathway, in different species”, Infinity Pharmaceuticals, Inc., Presentation Poster, 1 page (2008).
Mao et al., “First example of asymmetric transfer hydrogenation in water induced by a chiral amino alcohol hydrochloride”, Tetrahedron Letters, vol. 46, pp. 7341-7344 (2005),
Masamune et al., “11-Deoxojervine, a new alkaloid form Veratrum species”, Bull. Chem. Soc. Japan, vol. 38, No. 8, pp. 1374-1378 (1965).
Masamune et al., “Syntheses and NMR spectra of 22,27-imino-17,23-oxidojervane derivatives”, Tetrahedron, vol. 23, No. 4, pp. 1591-1612 (1967).
Masamune et al., “Synthesis of jervine and related alkaloids”, J, Am. Chem. Soc., vol. 89, No. 17, pp. 4521-4523 (1967).
Masamune et al., “The stereochemistry of dihydrojervine and related compounds: The ORD curves of 11-oxoetiojervanes and 11-oxoiminojervanes”, Tetrahedron, vol. 25, Issue 19, pp. 4853-4871 (1969).
Mazur, “Azasteroids III. 3-aza-a-homo androgens”, J. Org. Chem., vol. 28, pp. 248-250 (1963).
Meloni et al., “Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2”, Mol. Cell. Biol., vol. 26, No. 20, pp. 7550-7560 (2006).
Metcalfe and De Sauvage, “Hedgehog fight back: mechanisms of acquired resistance against smoothened antagonists”, Cancer Res; vol. 71, No. 15, pp. 5057-5061 and 6087 (2011).
Mrozik et al., “Heterocyclic steroids in the antiinflammatory series”, J. Med. Chem., vol. 7, pp. 584-589 (1964).
Müller-Röver et al., A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages, J. Invest. Dermatol., vol. 117, No. 1, pp. 3-15 (2001).
Nakamura et al., “Induction of osteogenic differentiation by hedgehog proteins”, Biochem. Biophys. Res. Comm., vol. 237, pp. 465-469 Article No. RC977156 (1997).
Niemann et al., “Indian hedgehog and β-catenin signaling: Role in the sebaceous lineage of normal and neoplastic mammalian epidermis”, PNAS, vol. 100, Suppl. 1, pp. 11873-11880 (2003).
Nolan-Stevaux et al., “GLI1 is regulated through smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation”, Genes Dev., vol. 23, No. 1, pp. 24-36 (2009).
Noyori and Hashiguchi, “Asymmetric transfer hydrogenation catalyzed by chiral ruthenium complexes”, Acc. Chem Res., vol. 30, No. 2, pp. 97-102 (1997).
Oatis et al., “Isolation purification and full NMR assignments to cyclopamine from veratrum californicum”, Chemistry Central Journal, vol. 2, No. 12, 17 pgs. (2008).
Ohta et al., “Investigations on steroids, XI. Synthesis of steroidal oxazole, imidazole, and triazole”, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1487-1497 (1968).
Ohta et al., “p53-independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma Cells”, Cancer Res., vol. 65, No. 23, pp. 10822-10829 (2005).
Oka and Hara, “Regiospecific Beckmann rearrangement of 3-oxo-4-ene steroid oximes”, J. Org. Chem., vol. 43, No. 19, pp. 3790-3791 (1978).
Oka and Hara, “Synthesis of A-azasteroids by the use of specific Beckmann rearrangement”, Chemistry and Industry, pp. 168-170 (1969).
Olive et al., “Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer”, Science, vol. 324, No. 5933, pp. 1457-1461 (2009).
Oro and Higgins, “Hair cycle regulation of hedgehog signal reception”, Dev. Biol., vol. 255, No. 2, pp. 238-248 (2003).
Paladini et al., “Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway”, J. Invest. Dermatol., vol. 125, No. 4, pp. 638-646 (2005).
Pan et al., “Discovery of NVP-LDE225, a potent and selective smoothened antagonist”, ACS Med. Chem. Lett., vol. 1, No. 3, pp. 130-134 (2010).
Park and Park, “Differential expression of Runx2 and indian hedgehog in cartilaginous tumors”, Pathol. Oncol. Res., vol. 13, No. 1, pp. 32-37 (2007).
Park et al., “A crucial requirement for hedgehog signaling in small cell lung cancer”, Nature Med., Author manuscript, vol. 17, No. 11, pp. 1504-1508, DOI: 10.1038/nm.2473 (2012).
Paryzek et al., “Ammonium formate/palladium on carbon: A versatile system for catalytic hydrogen transfer reductions of carbon-carbon double bonds”, Synthesis, No. 13, pp. 2023-2026 (2003).
Patil et al., “Hedgehog signaling in human hepatocellular carcinoma”, Cancer Biol. Ther., vol. 5, No. 1, pp. 111-117 (2006).
Peacock et al., “Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma”, PNAS USA, vol. 104, No. 10, pp. 4048-4053 (2007).
Peacock et al., “Visualization of Smoothened activation supports an essential role for hedgehog signaling in the regulation of self-renewal in small cell lung cancer”, Infinity Pharmaceuticals, Inc., 1 page (2009).
Penova and Trandafiloff, “Intensification of extraction processes with tensides”, Pharmazie, vol. 26, No. 8, pp. 489-490 (1971) With English Translation.
Philips et al., “Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer”, PLoS One, vol. 6, Issue 9, No. e23943, pp. 1-12 (2011).
Pietsch et al., “Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched”, Cancer Research, vol. 57, pp. 2085-2088 (1997).
Pink et al., “Activity of IPI-926, a potent HH pathway inhibitor, in a novel model of medulloblastoma derived from Ptch/HIC +/− mice”, Infinity Pharmaceuticals, Inc., AACR Meeting Abstracts Online, 99th AACR Annual Meeting, Apr. 13, 2008; San Diego, CA, Abstract #1588, Presentation Slides, 15 pages (2008).
Protor et al., “Hedgehog signaling in castration resistant prostate cancer”, AACR Annual Meeting, Apr. 17-21, 2010, Infinity Pharmaceuticals, Inc., Abstract #3857, Presentation Slides, 14 pages (2010).
Qualthrough et al., “Hedgehog signalling in colorectal tumour cells: induction of apoptosis with cyclopamine treatment” Int. J. Cancer, vol. 110, No. 6, pp. 831-837 (2004).
Quirk et al., “The smoothened gene and hedgehog signal transduction in Drosophila and vertebrate development”, Cold Spring Harbor Symposium Quant. Biol., vol. 62, pp. 217-226 (1997).
Rahman et al., “Alkaloids from veratrum album”, Phytochemistry, vol. 30, No. 1, pp. 368-370 (1991).
Rahman and Choudhary, “Chemistry and biology of steroidal alkaloids”, The Alkaloids, Cordell, et., Academic Press, San Diego, vol. 50, Ch. 2, pp. 61-108 (1998).
Rasmusson et al., “Azasteroids: structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding”, J. Med. Chem., vol. 29, pp. 2298-2315 (1986).
Ravasio and Rossi, “Selective hydrogenations promoted by copper catalysts. 1. Chemoselectivity, regioselectivity, and stereoselectivity in the hydrogenation of 3-substituted steroids”, J. Org. Chem., vol 56, No. 13, pp. 4329-4333 (1991).
Read, “Direct targeting of tumor cells with smoothed inhibitor IPI-926”, 2011 AACR Read IPI-926 Direct Targeting, Infinity Pharmaceuticals, Inc., Presentation Slides, 27 pages (2011).
Reddy et al., “A new novel and practical one pot methodology for conversion of alchohols to amines”, Synthetic Communications, vol. 30, No. 12, pp. 2233-2237 (2000).
Reetz and Li, “An efficient catalyst system for the asymmetric transfer hydrogenation of ketones: remarkably broad substrate scope”, J. Am. Chem. Soc., vol. 128, No. 4, pp. 1044-1045 (2006).
Reifenberger et al., “Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system”, Cancer Research, vol. 58, pp. 1798-1803 (1998).
Remingtons Pharmaceutical Sciences, 17th Edition, Gennaro, ed., Mack Publishing Company, Easton, Pennsylvania 18042, p. 1625 (1985).
Rohatgi et al., “Patched1 regulates hedgehog signaling at the primary cilium”, Science, vol. 317, No. 5836, pp. 372-376 (2007).
Rominger et al., “Evidence for aliosteric interactions of antagonist binding to the smoothened receptor”, J. Pharmacol. Exp. Ther., vol. 329, No. 3, pp. 995-1005 (2009).
Ross, “A Study Evaluating IPI-926 in combination with gemcitabine in patients with metastatic pancreatic cancer”, National Cancer Institute, Clinical Trials (PDQ®), Data processed on Oct. 17, 2013, 3 pgs., Retrieved from the internet http://www.cancer.gov/clinicaltrials/search/view?cdrid=674592&version=HealthProfessional.
Rubin and De Sauvage, “Targeting the hedgehog pathway in cancer”, Nature Rev., vol. 5, No. 12, pp. 1026-1033 (2006).
Rudin et al., “Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449”, N. Eng. J. Med., vol. 361, No. 12, pp. 1173-1178 (2009).
Rudin et al., “A phase 1 study of IPI-926, an inhibitor of the hedgehog pathway, in patients with advanced or metastatic solid tumors”, Infinity Pharmaceuticals, Inc., Poster, 1 page. (2010).
Saldanha, “The hedgehog signalling pathway and cancer”, J. Pathol., vol. 193, No. 4, pp. 427-432 (2001).
Sanganwar and Gupta, “Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide”, Int. J. Pharm., vol. 360, No. 1-2, pp. 213-218 (2008).
Sasson et al., “Homogeneous catalytic transfer-hydrogenation of a, β-unsaturated carbonyl compounds by dichlorotris (triphenylphosphine) ruthenium (II)”, Tetrahedron Letters, vol. 12, Issue. 24, pp. 2167-2170 (1971).
Sato et al., “Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog”, J. Clin. Invest., vol. 104, No. 7, pp. 855-864 (1999).
Sato et al., “Effect of adenovirus-mediated expression of sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia”, J. Natl. Cancer Inst., vol. 93, No. 24, pp. 1858-1864 (2001).
Sawada et al., “Asymmetric catalysis of intramolecular cyclopropanation of 5-aryl-1-diazo-1-mesitylsulfonyl-5-hexen-2-ones”, Adv. Synth. Catal., vol 347, Issue 11-13, pp. 1527-1532 (2005).
Shafaee et al., “Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in hedgehog expressing pancreatic cancer cells”, Cancer Chemother. Pharmacol., vol. 58, No. 6, pp. 765-770 (2006), Original Article, 6 pgs., DOI:10.1007/s00280-006-0227-4 (2006).
Shafiee et al., “Enzymatic deglycosylation of enfumafungin, a triterpene glycoside natural product, and its chemically synthesized analogues”, J. Mol. Catalysis B: Enzymatic, vol. 16, pp. 27-32 (2001).
Shaw et al., “The sonic hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts”, Oncogene, vol. 28, No. 50, pp. 4480-4490 (2009).
Sheng et al., “Activation of the hedgehog pathway in advanced prostate cancer”, Molecular Cancer, vol 3, No. 29, 13 pages (2004).
Sheng et al., “Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal”, J. Biol. Chem. vol 281, No. 1, pp. 9-12 (2006).
Shibasaki et al., “Hydrolysis of conjugated steroids by the combined use of β-glucuronidase preparations from Helix pomatia and Ampullaria: Determination of urinary cortisol and its metabolites”, Steroids, vol. 66, pp. 795-801 (2001).
Shin et al., “Hedgehog / WNT feedback supports regenerative proliferation of epithelial stem cells in bladder”, Nature, vol. 472, No. 7341, pp. 110-114, Author Manuscript, 15 pgs. (2011).
Shiotani et al., “Sonic hedgehog and CDX2 expression in the stomach”, J. Gastroenterol. Hepatol., vol. 23, Suppl. 2, pp. S161-S166 (2008).
Shner et al., “The sterospecificity of the hydrogenation of 16α-methyl-3-oxo-Δ4-unsaturated compounds”, Chemistry of Natural Compounds, vol. 6, No. 1 , pp. 48-51 (1970).
Shroff and Harper, “3-Aza-A-homoandrostenes” J. Med. Chem., vol. 12, No. 1, pp. 190-191 (1969).
Sicklick et al., “Hedgehog signaling correlates with hepatocellular carcinoma progression” J. Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, vol. 23, No. 16s (June 1 Supplement), Abstract #9610, 1 page (2005).
Sicklick et al., “Hedgehog signaling maintains resident hepatic progenitors throughout life”, Am. J. Physiol. Gastrointenst. Liver Physiol., vol. 290, No. 5, pp. G859-G870 (2006).
Sicklick et al., “Dysregulation of the hedgehog pathway in human hepatocarcinogenesis”, Carcinogenesis, vol. 27, No. 4, pp. 748-757 (2006).
Sims-Mourtada et al., “Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response”, Clin. Cancer Res., vol. 12, No. 21, pp. 6565-6572 (2006).
Singh et al., “Hedgehog-producing cancer cells respond to and require autocrine hedgehog activity”, Cancer Res.; vol. 71, No. 13, pp. 4454-4463 (2011).
Siu et al., “A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL 139), in subjects with advanced or metastatic solid tumors”, J. Clin. Oncol., vol. 28, pp. 15s, Suppl. Abstract #2501, 3 pgs.(2010) Abstract Only.
Skipper et al., “In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts”, ORL, vol. 71, No. 1, pp. 1-5, Original Paper, DOI:10.1159/000163217 (2009).
Skvara et al., “Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor”, J. Invest. Dermatol., vol. 131, No. 8, pp. 1735-1744 Original Article, DOI:10.1038/jid.2011.48 (2011).
Smith and Thomas, “Animal models for the study of squamous cell carcinoma of the upper aerodigestive tract: a historical perspective with review of their utility and limitations, Part A. Chemically-induced de novo cancer, syngeneic animal models of HNSCC, animal models of transplanted xenogeneic human tumors,” Int., J. Cancer, vol. 118, No. 9, pp. 2111-2122 (2006).
Stanton et al., “Small-molecule modulators of the sonic hedgehog signaling pathway”, Mol. Biosyst., vol. 6, pp. 44-54 (2010).
Stecca et al., “Melanomas require Hedgehog-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways”, PNAS, vol. 104, No. 14, pp. 5895-5900 (2007).
Steg et al., “Multiple gene expression analysis in paraffin-embedded tissues by TaqMan low-density array, application to hedgehog and Wnt pathway analysis in ovarian endometroid adenocarcinoma”, J. Mol. Diagn., vol. 8, No. 1, pp. 76-83 (2006).
Suggs et al., “Facile homogeneous hydrogenations of hindered olefins with [ir(cod)py(PCy3)]PF6”, Tetrahedron Letters, vol. 22, Issue 4, pp. 303-306 (1981).
Suginome et al., “Synthesis of O,N-diacetyl-3β-hydroxy-5α, 12α-jervan-11-one with 17-epi-configuration by hypoiodite reaction (1,2)”, Tetrahedron Letters, vol. 14, No. 42, pp. 4147-4150 (1973).
Suginome et al., “Photo-induced Radical Rearrangements of Hypoiodite of N-Acetyljervine and the Related C-nor-D-Homosteroid in the Presence of Mercury (II) Oxide and Iodine”, Bull. Chem. Soc. Japan, vol. 54, No. 10, pp. 3042-3047 (1981).
Suginome et al., “The transformation of Jervine into 18-Functional D-Homo-C-Norsteroids. IV. The Transformation of Jervine into (20R)-18,20-β-epoxy-3β-hydroxy-17β-ethyletiojervan-18-one 3-acetate via (20R)-18,20β-epoxy-3β-hydroxy-12α,17β-ethyletiojervan-11-one 3-acetate”, Bull. Chem. Soc. Jpn., vol. 54, No. 3, pp. 852-861 (1981).
Sydor et al., “Activity of IPI-926, a novel inhibitor of the HH pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHH ligand”, Eur. J. Cancer, Supplement, vol. 6, No. 12, p. 179, Poster 570 (2008).
Taipale et al., “Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine”, Nature, vol. 406, No. 6799, pp. 1005-1009 (2000).
Tannock et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer”, N. Engl. J. Med., vol. 351, No. 15, pp. 1502-1512 (2004).
Tas and Avci, “Rapid clearance of psoriatic skin lesions induced by topical cyclopamine”, Dermatology, vol. 209 pp. 126-131 (2004).
Thayer et al., “Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis”, Nature, vol. 425, pp. 851-856 (2003).
Thievessen et al., “J. Hedgehog signaling in normal urothelial cells and urothelial carcinoma cell lines”, J. Cell Physiol., vol. 203, No. 2, pp. 372-377 (2005) Abstract Only.
Travaglione et al., “Activity of IPI-926, a novel inhibitor of the Hh pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHh ligand”, Infinity Pharmaceuticals, Inc., Presentation Poster, 1 page (2008).
Travaglione et al., “A novel HH pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model”, AACR Meeting Abstracts Online, 99th AACR Annual Meeting, Apr. 12-16, 2008, San Diego, CA, Abstract #4611, 2 pags (2008).
Travaglione et al., “Induction of tumor-derived hedgehog ligand by chemotherapy”, Infinity Pharmaceuticals, Inc., Presentation Poster, Abstract #323, 1 page (2009).
Travaglione et al., “The Hh inhibitor IPI-926 enhances tumor perfusion and nab-paclitaxel activity in a pancreatic xenograft model”, Infinity Pharmaceuticals, Inc., Presentation Poster, Abstract #LB-374, 1 page (2010).
Tremblay et al., “Synthesis of novel, chemically stable D-homo-cyclopamine analogs via a cyclopropanation/ring-expansion sequence”, Infinity Pharmaceuticals, Inc., 1 page (2007).
Tremblay et al., “Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists”, J. Med. Chem., vol. 51, No. 21, pp. 6646-6649 (2008).
Tremblay et al., “Synthesis and structure activity relationship of D-homo cyclopamine analogs: 3-substituted analogs”, Infinity Pharmaceuticals, Inc., Presentation Poster, 1 page (2009).
Tremblay et al., “Discovery of IPI-926, a semi-synthetic clinical candidate that targets the hedgehog pathway”, Infinity Pharmaceuticals, ACS Meeting Salt Lake City, UT on Mar. 25, 2009, Presentation Slides, 26 pages (2009).
Tremblay et al., “Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)”, J. Med. Chem., vol. 52, No. 14, pp. 4400-4418 (2009).
Tremblay et al., “Recent patents for hedgehog pathway inhibitors for the treatment of malignancy”, Expert Opin. Ther. Pat., vol. 19, No. 8, pp. 1039-1056 (2009).
Tremblay et al., “New Developments in the discovery of small molecule Hedgehog pathway antagonists”, Curr. Opin. Chem. Biol., vol. 14, No. 3, pp. 428-435 (2010) Article in press, COCHBI-737, vol. 14, pp. 1-8 (2010).
Tremblay et al., “Development of multi-kilogram synthetic route to IPI-926, a novel hedgehog pathway antagonistic for the treament of malignant diseases”, Infinity Pharmaceuticals, Inc., Apr. 2, 2011, Presentation Slides, 29 pages (2011).
Tsuji et al., “Highly stereoselective hydrogenation of 3-oxo4-ene and -1,4-diene steroids to 5β compounds with palladium catalyst”, J. Org. Chem., vol. 45, pp. 2729-2731 (1980).
Turner et al., “Sonic hedgehog pathway inhibition alters epididymal function as assessed by the development of sperm motility”, Journal of Andrology, vol. 27, No. 2, pp. 225-232 (2006).
Van Der Horst et al., “Hedgehog stimulates only osteoblastic differentiation of undifferentiated KS483 cells”, Bone, vol. 33, No. 6, pp. 899-910 (2003).
Vanhook, “Focus issue: fine-tuning hedgehog signaling in development and disease”, Sci. Signaling, vol. 4, Issue 200, No. eg10, pp. 1-2 (2011).
Van Weerden et al., “Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer”, Br. J. Cancer, vol. 100, No. 1, pp. 13-18 (2009).
Veratrum nigrum, Wikipedia entry last updated Apr. 23, 2014, Retrieved from the internet http://en.wikipedia.org/wiki/Veratrum—nigram.
Villavicencio et al., “The sonic hedgehog-patched-gli pathway in human development and disease”, Am. J. Hum. Genet., vol. 67, No. 5, pp. 1047-1054 (2000).
Villavicencio et al., “Activity of the Hh pathway inhibitor IPI-926 in a mouse model of medulloblastoma”, Infinity Pharmaceuticals, Inc., Abstract #3199, Presentation Poster, 1 page (2009).
Voituriez and Charette, “Enantioselective cyclopropanation with TADDOL-derived phosphate ligands”, Adv. Synth. Catal., vol. 348, Issue 16-17, pp. 2363-2370 (2006).
Von Hoff et al., “Inhibition of the hedgehog pathway in advanced basal-cell carcinoma”, N. Eng. J. Med., vol. 361, No. 12, pp. 1164-1172 (2009).
Wang et al., “Revision of structure of peimisine”, Yao Xue Xue Bao, vol. 17, No. 4, pp. 273-278 (1992) Database Accession No. 1992:490583, (1992).
Wanshura et al., “Sequential activation of snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells”, Cancer Res.; vol. 71, No. 15, pp. 5336-5345 (2011).
Warzecha et al., “Inhibition of osteosarcoma cell proliferation by the hedgehog-inhibitor cyclopamine”, J. Chemother., vol. 19, No. 5, pp. 554-561 (2007).
Watkins et al., “Hedgehog signaling within airway epithelial progenitors and in small-cell lung cancer”, Nature, vol. 422, pp. 313-317 (2003).
Wei et al., “Indian hedgehog and its targets in human endometrium: menstrual cycle expression and response to CDB-2914”, J. Clin. Endocrinol. Metab., vol. 95, No. 12, pp. 5330-5337 (2010).
Williams et al., “Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions”, PNAS USA, vol. 100, No. 8, pp. 4616-4621 (2003).
Wintersteiner et al., “Structure of jervine, V. The sulfuric acid-catalyzed acetolysis of diacetyltetrahydrojervine”, J. Am. Chem. Soc., vol. 76, No. 22, pp. 5609-5616 (1954) Database Accession No. 1955:73588 (1954).
Wong et al., “Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis”, Nat. Med., vol. 15, No. 9, pp. 1055-1061 (2009).
Wu et al., “Chemical constituent of hubeibeimu, V. Isolation and identification of hupehenisine”, Yaoxue Xuebao, vol. 21, No. 7, pp. 546-550 (1986) Database Accession No. 1987:15699 (1987).
Wunder et al., “Opportunities for improving the therapeutic ratio for patients with sarcoma”, Lancet Oncol., vol. 8, No. 6, pp. 513-524 (2007).
Xie et al., “Activating smoothened mutations in sporadic basal-cell carcinoma”, Nature, vol. 391, pp. 90-92 (1998).
Yamakawa et al., “CH/π attraction: the origin of enantioselectivity in transfer hydrogenation of aromatic carbonyl compounds catalyzed by chiral η6-arene-ruthenium(II) complexes”, Angew. Chem. Int. Ed., vol. 40, No. 15, pp. 2818-2821 (2001).
Yang and Hinds, “pRb-mediated control epithelial cell proliferation and Indian Hedgehog expression in mouse intestinal development”, BMC Developmental Biology, vol. 7, No. 6, pp. 1-12 (2007).
Yauch et al., “Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma”, Science, vol. 326, No. 5952, pp. 572-574 (2009).
Yoo et al., “Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-β-mediated activation of the ALK5-smad 3 pathway”, Carcinogenesis, vol. 29, No. 3 pp. 480-490 (2008).
Yoshizaki et al., “Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis”, World J. Gastroenterol., vol. 12, No. 35, pp. 5687-5691 (2006).
Yu et al., “Chemical constituents of the unibract fritillary (Fritillaria unibracteata)”, Zhongcaoyao, vol. 21, No. 1, pp. 2-6 (1990), Database Accession No. 1990:512481 (1990).
Yun et al., “Simultaneous synthesis of enantiomerically pure (R)-1-phenylethanol and (R)-α-methylbenzylamine from racemic α-methylbenzylamine using ω-transaminase/alcohol dehydrogenase/glucose dehydrogenase coupling reaction”, Biotechnol. Lett., vol. 25, No. 10, pp. 809-814 (2003).
Yun et al., “ω-Amino acid: Pyruvate transaminase from Alcaligenes denitrificans Y2k-2: A new catalyst for kinetic resolution of β-amino acids and amines”, Appl. Environ. Microbiol., vol. 70, No. 4, pp. 2529-2534 (2004).
Zanotti-Gerosa et al., “Ruthenium-catalysed asymmetric reduction of ketones, diphosphine ligands in hydrogenations for pharmaceutical synthesis”, Platinum Metals Rev., vol. 49, No. 4, pp. 158-165 (2005).
Zassoinovich et al., “Asymmetric hydrogen transfer reactions promoted by homogeneous transition metal catalysts”, Chem. Rev., vol. 92, No. 5, pp. 1051-1069 (1992).
Zeisberg and Neilson, “Biomarkers for epithelial-mesenchymal transitions”, J. Clin. Invest., vol. 119, No. 6, pp. 1429-1437 (2009).
Zeng et al., “Neurosteroid analogues. 10. The effect of methyl group substitution of the C-6 and C7 positions on the GABA modulatory and anesthetic actions of (3α,5α)- and (3α,5β)-3-hydroxypregnan-20-one”, J. Med. Chem., vol. 48, No. 8, pp. 3051-3059 (2005).
Zhang et al., “Hedgehog pathway responsivenss correlates with the presence of primary cília on prostate stromal cells”, BMC Developmental Biology, vol. 9, No. 50, pp. 1-7 (2009).
Zhao et al., “Studies on the constituents of veratrum plants II. Constituents of Veratrum nigrum L. var. ussuriense (1). Structure and 1H- and 13C-nuclear magnetic resonance spectra of a new alkaloid, verussurinine, and related alkaloid”, Chem. Pharm. Bull., vol. 39, No. 3, 549-554 (1991).
Zhao et al., “Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia”, Nature, vol. 460, No. 7255, pp. 652-656 (2009) Pre-Publication Article DOI: 10.1038/nature07737, pp. 1-5 (2009).
International Search Report from International Patent Application No. PCT/US2016/035713, 8 pages, dated Nov. 9, 2016.
International Search Report from International Patent Application No. PCT/US2017/017247, 7 pages, dated Apr. 25, 2017.
Peluso et al., “Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity”, PLOS ONE, vol. 9, Issue 3, No. e90534, 11 pages (2014).

Related Publications (1)

	Number	Date	Country
	20160177354 A1	Jun 2016	US

Provisional Applications (1)

	Number	Date	Country
	61231439	Aug 2009	US

Continuations (3)

	Number	Date	Country
Parent	14257658	Apr 2014	US
Child	15054011		US
Parent	13175053	Jul 2011	US
Child	14257658		US
Parent	PCT/US2010/044597	Aug 2010	US
Child	13175053		US

Enzymatic transamination of cyclopamine analogs

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Disclaimer

Abstract

Description

Claims

Parent Case Info

US Referenced Citations (150)

Foreign Referenced Citations (70)

Non-Patent Literature Citations (291)

Related Publications (1)

Provisional Applications (1)

Continuations (3)